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ABSTRACT OF DISSERTATION

TIER 1 GENOMIC APPLICATIONS: A KENTUCKY STATE NEEDS
ASSESSMENT
Paper 1: An Assessment of Kentucky Cancer Registry Data for Appropriate
Referral to Genetic Services for Hereditary Breast and Ovarian Cancer
Syndrome and Lynch Syndrome, 2009-2012
BACKGROUND: It is estimated that over 1 million people in the United States
have Hereditary Breast and Ovarian Cancer syndrome (HBOC) or Lynch
syndrome (LS). Evidence-based guidelines for identifying individuals with HBOC
and LS are available, and the CDC has developed a toolkit to provide guidance
for the implementation of programs to increase identification of patients
appropriate for cancer genetic services. However, most individuals with HBOC
and LS remain undiagnosed. While some state public health departments have
pioneered programs in public health genetics, many states, including Kentucky,
have conducted little work in this area. This study utilizes Kentucky Cancer
Registry data to estimate the number of cases of breast, ovarian, fallopian tube,
colorectal and endometrial cancers diagnosed between 2009-2012 that would
meet guidelines for referral to genetic services in order to determine the state’s
need for public health genetics programs that target hereditary cancer
syndromes.
METHODS: Kentucky Cancer Registry data for all diagnoses of breast, ovarian,
fallopian tube, colorectal and endometrial cancers between 2009-2012 was
obtained. Evidence-based guidelines from NCCN, EGAPP, and ACMG/NSGC

were applied to the data to determine the number of cases that met criteria for
referral to genetic services. Descriptive statistics were performed to generate
count data and referral groups were compared using chi-square statistics. The
most recent year of data (2012) was used to analyze the distribution of cases
across Kentucky counties and Area Development Districts (ADDs).
RESULTS: Of the 28,109 cases of breast, ovarian, fallopian tube, colorectal, and
endometrial cancer diagnosed in Kentucky between 2009-2012, 15,477 (55.1%)
were determined to meet guidelines for referral including 4229 cases of breast
cancer, 1057 cases of ovarian and fallopian tube cancers, 9815 colorectal
cancers and 376 endometrial cancers. Chi-square analysis indicated that cases
in the referral group were more likely to be from individuals identified as black
(p=0.0005), individuals with late stage caners (p<0.0001), individuals from
Appalachian counties (p=0.0006) and individuals who are deceased (p<0.0001).
Analysis of cases by county show that 10% (12/120) Kentucky counties and 60%
of ADDs have genetic counseling services.
DISCUSSION: This study represents the first analysis of Kentucky Cancer
Registry data to identify cancer cases appropriate for referral to genetic services
and has identified that a significant number of cases each year would be
appropriate for referral. Identification of patients with HBOC and LS allow for the
appropriate planning for cancer prevention, screening, and treatment in both
index cases and their relatives. Population-based programs for the identification
and referral of patients who would benefit from genetic services should be
considered in Kentucky. In order to accommodate additional referrals that would
likely result, efforts should be made to expand the genetic counseling workforce
in Kentucky.

Paper 2: Utilizing Medicaid Claims Data to Assess the Use of Genetic Testing
for Hereditary Breast and Ovarian Cancer Syndrome in Kentucky and
Characteristics that Influence Genetic Testing Completion
BACKGROUND: Hereditary Breast and Ovarian Cancer syndrome (HBOC) is a
genetic condition that causes a significantly increased risk for breast, ovarian and
other cancers. Genetic testing of the BRCA1 and BRCA2 genes has been
available commercially for nearly 20 years; however, many individuals with
HBOC remain unaware of their increased cancer risks. Factors that affect
referral to and uptake of genetic counseling and testing have been previously
reported including race, age, physician type, marital status, increased risk for
breast cancer, and knowledge of genetics. This study utilizes Kentucky Medicaid
Claims data to examine how many individuals diagnosed with breast, ovarian or
fallopian tube cancer actually received genetic testing and to determine the
specific socio-demographic factors associated with obtaining genetic testing in
Kentucky.
METHODS: A cross-section of Kentucky Medicaid Claims data for the years
2009-2012 for individuals diagnosed with breast, ovarian or fallopian tube cancer
was utilized in this study to determine how many individuals appropriate for
genetic counseling and testing based on select NCCN guidelines actually
received this testing. Descriptive statistics were performed to generate count
data. T-test and chi-square tests were used to determine difference between
individuals who had a claim for genetic testing and individuals who did not.
Logistic regression was performed to determine variables that affected whether a
person had genetic testing while controlling for possible confounders.
RESULTS: This study found 3144 patients with a Medicaid claim between 20092012 who had a diagnosis of breast cancer and were age 50 or younger, male
breast cancer, ovarian or fallopian tube cancer. Of these individuals, 241 (7.7%)
also had a claim for genetic testing. Of individuals who were appropriate for
referral, 43.61% lived within 50 miles of a full-time, on-site genetic counseling
clinic, and distance from a genetic counseling clinic was not found to be

significantly associated with genetic testing. Logistic regression results showed
that the odds of having genetic testing decreased by 13.2% for every 5 years
increase in patient age (OR=0.868, p<0.0001). Being diagnosed with female
breast cancer (OR=9.137, p<0.0001), and having an appointment with a
gynecologist (OR=1.816, p=0.0083) or oncologist (OR=3.599, p<0.0001) were all
statistically significantly associated with an increase in the odds of receiving
genetic testing.
DISCUSSION: This study was the first to use Medicaid Claims data in Kentucky
to determine the use of genetic testing among individuals who meet evidencebased guidelines for referral to genetic services. This study found a low uptake
of genetic testing in this population (7.7%), although this is likely an
underestimate of the number of individuals who had genetic testing given that
this was a cross-sectional data set where individuals may have had genetic
testing outside of the study time frame. Given the results of this study, strategies
need to be considered by the public health workforce for increasing the number
of individuals at-risk for hereditary cancer syndromes who are referred to and
receive cancer genetic services. Continued research of the utilization of genetic
testing in Kentucky and barriers to referral and uptake of genetic testing need to
be done to further inform program development.

KEYWORDS: Public Health Genomics; Hereditary Breast and Ovarian
Cancer Syndrome; Colorectal neoplasms, Hereditary Nonpolyposis; Tier One
Genomic Applications; Bidirectional Cancer Registry Reporting, Kentucky
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A. INTRODUCTION
The Centers for Disease Control and Prevention (CDC) has designated
genetic counseling, family health history, and/or genomic testing for a number of
genetic diseases as Tier 1 Genomic Applications. These applications are based
on analytic validity, clinical validity, clinical utility and existing evidence-based
guidelines indicating that the use or test is ready for population-based
implementation 1,2. Inherited genetic syndromes with Tier 1 Applications include
Hereditary Breast and Ovarian Cancer (HBOC), Lynch syndrome (LS), Familial
Hypercholesterolemia (FH), and diseases included on the Newborn Screening
(NBS) Recommended Uniform Screening Panel (RUSP), among others 2. The
CDC recently published a Genomic Applications Toolkit that contains best
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practice examples for addressing the Tier 1 Genomic Applications at the level of
local and state health departments 3. Phase 1 approaches focus on several
broad activities including identifying individuals appropriate for testing, informing
policy, conducting surveillance, and providing education 3. These Phase 1
approaches can be used to prepare a state for cascade screening, which is the
main Phase 2 approach 3. Cascade screening is the process of identifying
individuals appropriate for genetic counseling and testing by systematically
offering services to the relatives of index cases found to have one of the included
genetic disorders. To date, few states have started the process of developing
programs to address Tier 1 Genomic Applications.
Two of the genetic conditions with tier 1 genomic applications are HBOC
and LS, which are the primary focus of this dissertation. It is estimated that
1/500 to 1/300 individuals in the general population have a BRCA1 or BRCA2
mutation, either of which causes HBOC 4. Approximately 5% of female breast
cancer (9.5% of breast cancers diagnosed under age 50), 25% or more of male
breast cancers, up to 18% of ovarian cancers, and up to 30% of fallopian tube
cancers are due to mutations in BRCA1 and BRCA2 5–8.
LS is caused by mutations in one of five known genes: MLH1, MSH2,
MSH6, PMS2, and EPCAM. LS has a population prevalence as high as 1 in 440
and is responsible for an estimated 2-4% of colorectal cancer diagnoses9–12.
Individuals with LS have an increased risk for colorectal, endometrial, ovarian,
stomach, small bowel, hepatobiliary tract, urinary tract, brain and central nervous
system, and skin cancers over the person’s lifespan13.
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Although individuals with HBOC and LS have a significantly increased
lifetime risk for certain cancers, there are steps that can be taken to prevent
cancer or diagnose it early when people know that they are at increased risk.
Individuals with HBOC or LS can undergo preventive surgery, pursue increased
screening for certain cancers, and/or take medications to reduce cancer risk12–15.
Furthermore, family members of individuals with HBOC or LS may also be at
very high risk for cancer and could benefit greatly from knowing this information
and pursuing preventive measures. Thus, utilizing the CDC Toolkit to implement
genomics programs to increase the use of this primary prevention measure may
have a significant impact on reducing cancer incidence and deaths. Currently,
genetic risk assessment and testing for HBOC and LS are not offered to all
appropriate patients. A recent study found that physicians correctly identified
only 41% of women at high risk for HBOC and referred them for genetic
counseling and testing 16. In a study conducted in Louisville, Kentucky, clinic
appointments were reviewed over a one year period, identifying over 500 women
who were appropriate for genetic counseling for HBOC, but had not been
previously referred. 17.
All states in the United States have been involved with the provision of
public health genetic services since 1985, when Mississippi became the last
state to implement a state newborn screening program

18.

More recently, some

states have been working on state needs assessments, planning, and program
implementation to further incorporate genomics into state public health
programs19. To date, Kentucky has not implemented any official programs in
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local or state health departments to address the CDC Tier 1 Genomic
Applications. However, Kentucky does have a number of assets that can be
utilized to prepare for and implement Phase 1 programs. One example is the
robust Kentucky Cancer Registry that collects data on every case of cancer
diagnosed in the state. Guidelines from the National Comprehensive Cancer
Network (NCCN), Evaluation of Genomic Applications in Practice and Prevention
(EGAPP) workgroup, the American College of Medical Genetics (ACMG), and
the National Society of Genetic Counselors (NSGC) for identifying individuals at
risk for hereditary cancer syndromes could be used to screen the Kentucky
Cancer Registry data already being collected12–14,20. This could lead to bidirectional cancer registry reporting, which involves a two-way exchange of
information between the state cancer registry and reporting institutions in the
state including hospitals and physician offices, being implemented through the
Kentucky Cancer Registry office and the Kentucky Department of Public Health.
In a bidirectional cancer registry reporting system, an algorithm developed from
national guidelines is applied to data already being collected by the state cancer
registry to identify individuals who are potentially at increased risk for HBOC and
LS. Information about patients who are potential candidates for genetic
counseling and testing, as well as educational information, is reported back to
cancer registrars, physicians, hospital administrators, and/or patients to assist
providers in referring patients and their relatives to appropriate services for
genetic risk assessment and testing21.

4

There are a number of barriers to implementing Phase 1 programs from
the CDC Genomics Application Toolkit in Kentucky. First, funding for public
health genetics and genomics projects is limited, and implementation would likely
require significant staff hours and materials costs. At this time, Kentucky has few
individuals in the Kentucky Department of Public Health with experience in
genetics, and furthermore, the state does not have an adequate supply of
genetics professionals to provide appropriate services to new individuals who are
identified for genetic risk assessment. In addition, many public health providers,
healthcare providers, and lay people know very little about inherited genetic
conditions and the importance of genetic counseling and testing. Educational
materials and programs would need to be developed in order to prepare the
public health and medical workforce for a public health program that addresses
screening for HBOC, LS, or other disorders with tier 1 genomic applications.
Finally, there have been few previous studies in Kentucky that have attempted to
quantify the number of individuals at risk for HBOC, LS and the other conditions
included in the Tier 1 Genomic Applications.

B. PROBLEM STATEMENT
Genetic counseling and/or testing for HBOC and LS has been available for
approximately twenty years. The provision of these services has traditionally
been based on a medical provider-patient model where patients are referred for
counseling and testing by a physician or other health care provider. In order for
this to occur, personal and family history should be collected for each patient and
5

addressed by the health care provider. Individuals referred for services are
typically seen on an individual basis by a genetic counselor and/or other provider.
Given the growing body of knowledge regarding HBOC and LS, the type of
people who are appropriate for counseling and testing is growing, and the
importance of family history in recognizing these syndromes, while still important
in many situations, has been shifting to broader population-based models for
identification of at-risk individuals 7,8,22,23. This shift in thinking about patient
identification for genetic services is likely to assist in the identification of
individuals who are appropriate candidates for genetic counseling and testing by
increasing provider and public awareness about the disease. However, a shift to
a public health model will require a significant amount of preparation and
planning as most public health departments and programs have had little
experience with genetics and genomics outside of state newborn screening
programs.
The recognition that genetics and genomics is becoming an important aspect
of public health is reflected in the addition of genomic goals to the Healthy
People 2020 goals for first time. Healthy People 2020 goals are evidence-based
goals for health improvement in the United States over a ten year period. The
Healthy People 2020 goal in genomics is to, “Improve health and prevent harm
through valid and useful genomic tools in clinical and public health practices” 24.
A specific objective of the goal relating to HBOC is to, “Increase the proportion of
women with a family history of breast and/or ovarian cancer who receive genetic
counseling,” from 34.6% to 38.1% (10% increase) 24. Select state and national
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public health organizations are now taking steps toward implementing programs
in an effort to meet these goals.
In order to implement public health genomic programs in the near future,
states must assess their current strengths, weaknesses, opportunities and goals
regarding public health genetics. Data will be required to identify the needs of
the state’s population, disparities in access to genetic services, and the capacity
of the state to assure the provision of services to residents. Currently, Kentucky
lacks public health genetics capacity outside of the state newborn screening
program and has little available data regarding public health genetics activities.
Furthermore, the state is currently serviced by only 19 genetic counselors, or 1
genetic counselor per 232,000 individuals 25,26. While other states have pursued
data collection studies and implemented programs to increase education,
surveillance of, and access to genetic counseling and testing among their
residents 27–30, Kentucky has done little to collect the data needed to assess the
needs and capacity of the state to identify individuals appropriate for genetic
services encompassed by the CDC Tier 1 Genomic Applications and to assure
access to those services.

C. PURPOSE OF DISSERTATION
To date, the presence of genetics and genomics in public health has been
exemplified by state newborn screening programs, which screen nearly all infants
born in the U.S. for severe inherited diseases including metabolic, endocrine,
hemoglobin and other disorders 31. However, evidence-based guidelines for
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identifying and diagnosing other genetic diseases, including HBOC and LS,
across the lifespan have recently been developed where public health programs
could play an important role in implementation12–14,20. The CDC has recognized
that these genetic diseases have Tier 1 Genomic Applications, and is calling on
state and local health departments to take action in the areas of policy,
education, surveillance, and clinical intervention as the first steps to developing
public health programs regarding these diseases 1.
This dissertation will encompass the first steps in a Kentucky state needs
assessment for implementing Tier 1 Genomic Applications. The dissertation will
provide information on two of the three Public Health Core Functions—
assessment and assurance—with a focus on HBOC and LS. The results of the
dissertation will provide information on Kentucky’s strengths, opportunities and
barriers to implementing public health based programs to promote genetic
counseling and testing. This will allow for future informed program planning to
address HBOC, LS, and other Tier 1 Genomic Applications to best meet the
unique needs of Kentuckians. Specifically, the first study will address public
health surveillance by utilizing Kentucky Cancer Registry data to assess
individuals diagnosed with breast, ovarian, fallopian tube, colorectal and
endometrial cancers in Kentucky to determine how many of these individuals
would be appropriate for referral to cancer risk assessment services based on
select NCCN, USPSTF (United States Preventive Services Task Force), EGAPP,
and ACMG/NSGC guidelines 12–14,32. This analysis will provide the first estimate
of how many individuals diagnosed with these cancers in Kentucky may benefit
8

from HBOC and LS genetic counseling and testing. It will also examine the
potential contribution of HBOC and LS to late stage cancers and the distribution
of at-risk individuals across the state. Study two will utilize Medicaid data to
determine what characteristics might influence an individual’s access to genetic
testing for HBOC. The study will detect potential barriers to and disparities in
care that may be encountered as larger public health programs that aim to
identify and refer individuals to genetic services are developed.
Aggregated together, the results of the two studies encompassed in this
dissertation will provide some of the groundwork needed for Kentucky to begin to
address public health genetics and genomics in the state. More work will need to
be done, but this dissertation should provide the preliminary information needed
to begin to build the funding and infrastructure for further assessment and
program implementation. Addressing inherited causes of common diseases in
Kentucky could contribute significantly to reducing diagnoses of and/or deaths
from these diseases.
D. RESEARCH QUESTIONS
This dissertation focuses on the following research questions as the basis for
conducting the first steps of a Kentucky state needs assessment for the
implementation of Tier 1 Genomic Applications:
1. How many patients diagnosed with breast, ovarian, fallopian tube,
colorectal, and endometrial cancer in Kentucky between January 2009
and December 2012 meet certain NCCN, EGAPP, or ACMG/NSGC
guidelines for genetic risk assessment referral? (Assessment)
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2. What is the contribution of breast, ovarian, fallopian tube, colorectal and
endometrial cancers that are likely due to HBOC or LS to the incidence of
late stage cancers and cancer mortality in Kentucky? (Assessment)
3. What is the availability of genetic counseling services to individuals at risk
for HBOC and LS? (Assurance)
4. What characteristics influence whether an individual diagnosed with
breast, ovarian, or fallopian tube cancer in Kentucky who is eligible for
genetic testing receives genetic testing of the BRCA1 and BRCA2 genes?
(Assessment)
E. RESEARCH HYPOTHESES
Study 1: An Assessment of Kentucky Cancer Registry Data for Appropriate
Referral to Genetic Services for Hereditary Breast and Ovarian Cancer
syndrome and Lynch syndrome, 2009-2012
Hypothesis: There are not a significant number of individuals diagnosed
with breast, ovarian, fallopian tube, colorectal, and endometrial cancers who
are appropriate for genetic counseling and testing services in Kentucky, and
currently the available genetic services are sufficient to meet this need.
Study 2: Utilizing Medicaid Claims Data to Assess the Use of Genetic Testing
for Hereditary Breast and Ovarian Cancer Syndrome in Kentucky and
Characteristics that Influence Genetic Testing Completion
Hypothesis: There are no significant differences between individuals who
are appropriate for genetic testing for HBOC and receive vs. do not receive
testing.
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F. SCOPE AND IMPORTANCE
It has been recognized by the CDC that involvement of state and local health
departments in public health genomics will be vital for the appropriate
identification and care of individuals at risk for genetic diseases over the lifespan
1,27.

The information generated from this dissertation will yield the first

surveillance data in Kentucky regarding the need for public health genomics
programs for HBOC and LS. The results of these studies will also contribute to
the growing body of state specific literature on public health genomics issues.
Although needs assessment for public health genomics has been done in other
states, specific information about the population of Kentucky will lay the
groundwork for further research and program implementation locally. This is
fundamentally important to the health of Kentucky residents, especially given that
the state has highest cancer incidence rate among the fifty states and District of
Columbia 33. Furthermore, in March 2014, Kentucky Governor Steve Beshear
announced the KY Health Now goals, which include reducing Kentucky cancer
deaths by 10% by 2019 34. A significant proportion of certain cancers are caused
by genetic conditions with Tier 1 genomic applications, with HBOC being
responsible for approximately 5% of female breast cancer (9.5% of breast
cancers diagnosed under age 50) and 18% of ovarian cancers5,6,8 and LS being
responsible for 2-4% of colon cancers 12. Identifying individuals at risk for these
diseases can allow for prevention of disease, appropriate treatment, or early
diagnosis through increased screening. Focusing on primary prevention in the
individuals most at risk for these common diseases would be expected to
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significantly contribute towards meeting the KY Health Now goals, especially
when combined with other efforts in the state to decrease environmental and
lifestyle risks.
G. LIMITATIONS AND DELIMITATIONS
Each of the studies included in this dissertation have unique limitations, which
are discussed in subsequent chapters. More broadly, the studies are secondary
data analyses, which are associated with specific limitations including not having
access to some important data points that could make the study more robust and
the researchers not having direct control over data quality. However, the
secondary data is being obtained from two high quality data sets—the Kentucky
Cancer Registry and Kentucky Medicaid Claims—which help to minimize these
concerns.
This dissertation includes two studies that represent the beginning of a needs
assessment in Kentucky for public health genomics, but is not comprised of all
the necessary components for a complete state needs assessment.
Furthermore, the dissertation focuses on HBOC and LS, and additional research
will need to be done to address other diseases with Tier 1 Genomic Applications.
An additional delimitation of this dissertation is lack of generalizability. The
data involved in each study is specific to the state of Kentucky, so results may
not be able to be generalized to needs in other states. This is an appropriate
approach to this project as public health genetic and genomic programs have
traditionally been developed and implemented on a state-by-state basis, allowing
states to tailor programs to coincide with state health initiatives and to reflect the
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needs of the state’s population. Although the results of this study cannot be
generalized outside of Kentucky, the methods used in each of the studies can
certainly be applied in other states as part of a needs assessment for public
health genomic programs.
H. ADVANCE ORGANIZER FOR DISSERTATION
The chapters of this dissertation are organized to reflect the two papers
generated by the research project, each of which has a self-contained literature
review, methods, results, and discussion section. The present chapter (Chapter
I) provides an introduction to the body of work encompassed in subsequent
chapters. Chapter II is the paper generated from Study 1, An Assessment of
Kentucky Cancer Diagnoses for Appropriate Referral to Genetic Services for
Hereditary Breast and Ovarian Cancer, 2009-2012. Chapter III contains the
paper from Study 2, Characteristics that Influence Genetic Testing Completion
for Hereditary Breast and Ovarian Cancer in Kentucky. Chapter IV provides a
summary of the conclusions from the body of research as well as
recommendations for future research and public health program implementation.
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CHAPTER 2
PAPER 1: AN ASSESSMENT OF KENTUCKY CANCER
REGISTRY DATA FOR APPROPRIATE REFERRAL TO GENETIC
SERVICES FOR HEREDITARY BREAST AND OVARIAN CANCER
SYNDROME AND LYNCH SYNDROME, 2009-2012

A. INTRODUCTION
B. MATERIALS AND METHODS
C. RESULTS
D. DISCUSSION

A. INTRODUCTION
Hereditary Breast and Ovarian Cancer syndrome (HBOC) and Lynch
syndrome (LS) are two hereditary cancer syndromes that cause an increased
lifetime risk for specific cancers in affected individuals. It is estimated that over
one million people in the United States have HBOC or LS1. HBOC caused by
mutations in the BRCA1 and BRCA2 genes is associated with up to a 71%
lifetime risk for breast cancer and up to a 46% lifetime risk for ovarian, fallopian
tube and primary peritoneal cancer2. HBOC is responsible for approximately 5%
of female breast cancer (9.5% of breast cancers diagnosed under age 50), 25%
or more of male breast cancers, up to 18% of ovarian cancers, and up to 30% of
fallopian tube cancers3–6. LS causes a 45% or greater lifetime risk for colorectal
cancer as well as increased risks for other cancers including endometrial,
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ovarian, stomach, hepatobiliary tract, urinary tract, small bowel, and brain/central
nervous system cancers7,8. Approximately 2-4% of colorectal cancers are due to
LS7.
Individuals who have already been diagnosed with cancer that is found to be
due to HBOC or LS are at a significantly increased risk for developing a second
cancer in the future. Their relatives are at risk for also having the inherited
cancer syndrome, with first degree relatives (parents, siblings, children) having a
50% chance to inherit the disease-causing, germ-line mutation, and second
degree relatives (grandparents, aunts, uncles, nieces, nephews, grandchildren,
etc.) having a 25% chance to inherit the mutation. Other, more distant family
members are also at risk for carrying the same genetic mutation. Therefore, the
identification of index cases in families with HBOC or LS has the potential to not
only help the individual best manage his or her cancer risk in the future, but also
to help additional family members prevent cancer or take steps to diagnose
cancer at the earliest possible stage through increased screening. The process
of systematically identifying at-risk relatives of an index case has been termed
cascade screening, and is recommended by the CDC as the method for Phase II
implementation of the Tier 1 Genomic Applications.9
Identifying individuals and their family members with a significantly increased
risk for cancer is a way of utilizing a primary prevention measure to reduce
cancer incidence and deaths. While individuals with HBOC and LS have
significantly increased lifetime cancer risks compared to the general population,
there are preventive measures including surgical interventions, increased
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screening, and medications that can be taken to reduce their cancer risks or
diagnose a cancer at the earliest possible stage.
Several organizations have published national guidelines for the identification
of individuals at risk for HBOC and LS. In 2013 the U.S. Preventive Services
Task Force (USPSTF) released guidelines for identifying unaffected women with
a family history of breast or ovarian cancer who are appropriate for genetic
counseling and testing2. In 2009, the Evaluation of Genomic Applications in the
Practice and Prevention (EGAPP) workgroup published guidelines on identifying
individuals newly diagnosed with colorectal cancer who have Lynch syndrome 7.
The American College of Medical Genetics (ACMG) and the National Society of
Genetic Counselors (NSGC) recently published joint guidelines for referral to
genetic counseling for multiple hereditary cancer syndromes, including HBOC
and LS10. The National Comprehensive Cancer Network (NCCN) releases
regularly updated guidelines for the identification of individuals with and without
cancer who are at risk for HBOC or LS8,11. Despite these available guidelines,
most individuals with HBOC and LS remain undiagnosed.
HBOC and LS have been designated by the CDC as conditions with Tier 1
Genomic Applications, which are family history and genetic testing applications
with significant evidence, validity and utility to support implementation into public
health practice 12. The CDC has released a toolkit for local and state health
departments to help these entities implement programs for the education,
identification, and screening of individuals at increased risk for HBOC, LS, and
other conditions 9. The toolkit outlines two phases of implementation, with Phase
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I implementation including bi-directional cancer registry reporting, providing
guidance for evidence-based policy making, developing data collection tools and
tracking data on the implementation of Tier 1 Genomic Applications, and
providing education and outreach to providers and the public.9 Phase II
implementation focuses on cascade screening programs9.
Existing data sources represent an important resource that can be utilized to
advance the implementation of Tier 1 Genomic Applications. One existing data
source, state cancer registries, contains important information that has the
potential to be used to identify individuals who are at risk for HBOC and LS. In
the U.S., each state maintains a central cancer registry that collects detailed
information on each case of cancer that is diagnosed in the state for public health
purposes. Typically, a standard set of information about each diagnosis of cancer
is reported from cancer registries at healthcare institutions to the state cancer
registry. This results in a comprehensive, population-based dataset that can be
used to address state and national surveillance and research questions
regarding cancer. Bidirectional cancer registry reporting is a process where an
algorithm developed from national guidelines is applied to the data already being
collected by the state cancer registry to identify specific sets of individuals who
are at increased risk for HBOC and LS13.
Several states have already utilized cancer registry data in implementing
Phase I recommendations, specifically in the creation of bidirectional cancer
registry programs9,14,15. Michigan, Connecticut, Colorado, and Oregon have used
cancer registry data in the implementation of bidirectional cancer registry
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reporting programs to identify individuals diagnosed with cancer who were at risk
for having HBOC and/or LS13. This information was then reported back to
institutions, physicians and/or patients. Although bidirectional cancer registry
reporting programs will vary by state depending on resources, state law, and
infrastructure, all programs will begin with an analysis of cancer registry data in
order to identify those patients who are potentially at risk for HBOC and/or LS.
There are some states that have pioneered programs for addressing the CDC
Tier 1 Genomic Applications, established public health genetics and genomics
programs, and secured funding for public health genetics programs15. In
contrast, most states, including Kentucky, have conducted little work in this area.
A data analysis to determine the impact of a bidirectional cancer registry
reporting program has not been conducted in Kentucky. The first step to
program implementation is a demonstration of need, and this study aims to
estimate the number of cases of newly diagnosed breast, ovarian, fallopian tube,
colorectal and endometrial cancers that would meet certain national guidelines
for genetic risk assessment referral for HBOC and LS. This study will provide
information regarding the current need for genetic counseling and testing for
HBOC and LS in Kentucky and provide preliminary information for use in the
planning and implementation of public health programs to increase awareness
and utilization of cancer genetic services.
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B. MATERIALS AND METHODS
Data Source
The data set analyzed for this study was obtained from the Kentucky Cancer
Registry located in Lexington, KY. The Kentucky Cancer Registry is the state
cancer registry, which collects data on each case of cancer diagnosed in the
state of Kentucky. Beginning in 1994, Kentucky state law KRS 214.556 requires
all Kentucky hospitals, their associated outpatient facilities, and other health care
facilities that diagnose or treat cancer patients to report every case of cancer
diagnosed to the registry16. Each year, the registry receives data on the over
28,000 primary cancer cases diagnosed in Kentucky residents16. Quality control
is addressed through a number of measures including the re-abstraction of a
subset of cases by cancer registrars employed by the registry 16. This process
increases the validity and reliability of the data to represent an accurate picture of
cancer diagnoses in Kentucky. However, threats to validity and reliability may
include incomplete or inaccurate information recorded in patient medical records,
cases not reported to or identified by the registry, and/or mistakes in abstracting
that cannot be detected through the extensive edit checks implemented in
software applications used to capture registry data. Complete, population-based
data is currently available in the Kentucky Cancer Registry through 2012.
The data subset used in this study was obtained from the Kentucky Cancer
Registry after completing the appropriate application for release of data and
obtaining IRB approval from the University of Kentucky IRB. Breast, ovarian, and
colorectal cancer cases were selected based on cancer site and year of
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diagnosis. Fallopian tube and endometrial cancers were selected based on
cancer site, histology and year of diagnosis. The final data subset contained
case based information. While individual patients may have had multiple cancers
diagnosed during the study period, this could not be determined from the data
set, and each diagnosis was considered separately. The cross sectional data
subset included 28,109 observations, which represent all cases of breast
(n=14,812), ovarian (n=1036), fallopian tube (n=121), colorectal (n=9815) and
endometrial (n=2325) cancers diagnosed in Kentucky from 2009-2012.
Data Analysis
The data set was reviewed and then loaded into SAS version 9.3 and R
version 3.1.3, which were used to conduct the data analysis. The data set
contains no missing data values. Descriptive statistics were run to generate
count data to measure the number of individuals newly diagnosed with breast,
ovarian, fallopian tube, colorectal and endometrial cancer each year who would
be appropriate for referral to genetic services. Chi-square analyses were used to
determine whether there were statistically significant differences between cases
that did and did not meet the referral guidelines examined in this study.
The following national guidelines were used to identify which cases were
appropriate for genetic counseling and testing:
Hereditary Breast and Ovarian Cancer syndrome (NCCN Criteria)11


Women diagnosed with breast cancer ≤ 50y



Women diagnosed with triple negative breast cancer
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Women diagnosed with epithelial ovarian or fallopian tube cancer at any
age



Men diagnosed with breast cancer at any age

Lynch syndrome


Any individual diagnosed with colorectal cancer (EGAPP)7



Endometrial cancer diagnosed at age < 50y10

The data set was then subdivided into four sub-sets based on these criteria:
1) Breast cancer cases that were diagnosed at age 50 or younger, breast cancer
cases diagnosed in a male, or breast cancer cases that were triple negative (ER,
PR and HER2 negative) at any age, 2) Ovarian cancer cases excluding
histologies that are known not to be associated with hereditary breast and
ovarian cancer syndrome (mucinous tumors, germ cell tumors, neuroendocrine
tumors and benign tumors 6,17) or fallopian tube cancer cases, 3) Colorectal
cancer cases, and 4) Endometrial cancer cases under age 50. Additional
descriptive statistics were generated for each sub-set of data.
The numbers of cancer diagnoses meeting the above stated criteria for
appropriate referral to genetic counseling and/or testing in 2012 were calculated
for each county in Kentucky as well as the 15 Kentucky Area Development
Districts (ADDs). The locations of cancer genetic counseling clinics and outreach
services were obtained through key informant interviews with genetic counselors
in the state of Kentucky. This information was used to determine the number of
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genetic counselors in the state as well as which counties and ADDs had access
to genetic counseling services.

C. RESULTS
A total of 28,109 breast, ovarian, fallopian tube, colorectal and endometrial
cancer cases diagnosed between 2009-2012 were included in the original data
set. Of these cancers, 4847 (17.2%) were diagnosed at or before age 50. In this
data set, 92.7% of cancer cases were diagnosed in individuals whose race was
identified as white, 6.8% in individuals identified as black, and 0.53% in
individuals of other races. Cancer stage at diagnosis was also evaluated using
the variable best stage group, which is derived from the collaborative stage and
incorporates both pathological and clinical stages18. While the majority of
cancers (70.1%) were diagnosed at an early stage (Stage 0, 1 or 2) as defined
by the best stage group (a calculated registry value from the pathological and
clinical TNM stage groups), this varied by cancer type with early stage diagnoses
occurring more often in breast (83.18% of cancers) and endometrial (75.57%)
cancers and less often in colorectal (53.57%) and ovarian/fallopian tube
(31.72%) cancers. Cases diagnosed in Appalachian counties comprised 27.98%
of all cancer diagnoses in the data set. Descriptive statistics for the full data set
are summarized in Table 1.
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Table 1: Full sample demographics

Breast
(n=14,812)
Age at dx

Ovarian/FT
(n=1157)

Colorectal
(n=9,815)

Endometrial
(n=2,325)

Total
(n=28,109)

N

%

N

%

N

%

N

%

N

%

< 35 years

225

1.52%

34

2.94%

98

1.00%

46

1.98%

403

1.43%

35-50 years

2919

19.71%

180

15.56%

1015

10.34%

330

14.19%

4444

15.81%

51-65 years

5806

39.20%

421

36.39%

3269

33.31%

1158

49.81%

10654

37.90%

> 65 years

5862

39.58%

522

45.12%

5433

55.35%

791

34.02%

12608

44.85%

84

0.57%

0

0.00%

5107

52.03%

0

0.00%

5191

18.47%

14728

99.43%

1157

100.00%

4708

47.97%

2325

100.00%

22918

81.53%

White

13596

91.79%

1098

94.90%

9033

92.03%

2180

93.76%

25907

92.17%

Black

1075

7.26%

52

4.49%

669

6.82%

122

5.25%

1918

6.82%

Other

82

0.55%

6

0.52%

49

0.50%

11

0.47%

148

0.53%

Unknown
Year of
Diagnosis

59

0.40%

1

0.09%

64

0.65%

12

0.52%

136

0.48%

2009

3637

24.55%

292

25.24%

2515

25.62%

522

22.45%

6966

24.78%

2010

3631

24.51%

282

24.37%

2416

24.62%

543

23.35%

6872

24.45%

2011

3698

24.97%

280

24.20%

2414

24.60%

588

25.29%

6980

24.83%

2012

3846

25.97%

303

26.19%

2470

25.17%

672

28.90%

7291

25.94%

Stage ≤ 2

12320

83.18%

367

31.72%

5272

53.71%

1757

75.57%

19716

70.14%

Stage 3 or 4
Other/Unknow
n
Appalachia
County

2077

14.02%

680

58.77%

3757

38.28%

339

14.58%

6853

24.38%

415

2.80%

110

9.51%

786

8.01%

229

9.85%

1540

5.48%

Appalachian
NonAppalachian

3757

25.36%

337

29.13%

3011

30.68%

759

32.65%

7864

27.98%

11055

74.64%

820

70.87%

6804

69.32%

1566

67.35%

20245

72.02%

Sex
Male
Female
Race

Cancer Stage

When the previously described evidence-based guidelines for referral to
genetic services are applied to this data set, 15,477 (55.1%) of the 28,109 cases
were determined to be appropriate for referral. Of the 14,812 cases of breast
cancer diagnosed between 2009 and 2012, 4229 (28.55%) were included in the
final data set because they were found to be diagnosed at or younger than age
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50, to have triple negative breast cancer, or to be male. Of the 1157 women who
were diagnosed with ovarian and fallopian tube cancer in 2009-2012, 1057
(91.36%) were included in the data sent, including 936 ovarian cancers with
histologies consistent with a possible hereditary ovarian cancer and all fallopian
tube cancers (121 cases). In the original data set, 2325 women were diagnosed
with endometrial cancer, and 376 (16.17%) were diagnosed at or under age 50,
thus meeting criteria for inclusion in the final data set. All cases of colorectal
cancer are appropriate for referral based on the EGAPP guidelines and included
in the final data set. Cases identified as being appropriate for referral to genetic
services are summarized in Table 2.
Table 2: Cancer Cases Appropriate for Referral to Genetic Services
Breast

Ovarian/FT

Colorectal

Endometrial

All Cases

3637

292

2515

522

Appropriate Referrals

1054

256

2515

94

28.98%

87.67%

100.00%

18.01%

All Cases

3631

282

2416

543

Appropriate Referrals

1008

259

2416

79

27.76%

91.84%

100.00%

14.55%

All Cases

3698

280

2414

588

Appropriate Referrals

1065

256

2414

95

28.80%

91.43%

100.00%

16.16%

All Cases

3846

303

2470

672

Appropriate Referrals

1102

286

2470

108

28.65%

94.39%

100.00%

16.07%

All Cases

14812

1157

9815

2325

Appropriate Referrals

4229

1057

9815

376

28.55%

91.36%

100.00%

16.17%

2009

Percent
2010

Percent
2011

Percent
2012

Percent
Total

Percent
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Cases that were identified as appropriate for referral to genetic services were
further analyzed to determine the race, sex (where applicable), stage (best stage
group), year of diagnosis, vital status and Appalachian county designation of
identified cases. The demographics of the cases meeting criteria for referral for
each cancer type are summarized in Table 3. These demographics represent in
part the referral criteria used in this study. For example, 74.34% of breast cancer
cases included in the referral data set where diagnosed at or under age 50,
which is mainly due to one of the criteria for referral being age of diagnosis with
breast cancer at or under age 50. Furthermore, 62.06% of ovarian and fallopian
tube cancers were diagnosed at stages 3 or 4, which is likely representative of
ovarian and fallopian tube cancers in general being fast-growing, aggressive
cancers that are often diagnosed at later stages. Alternately, the cases for the
three other cancer types had less than half of the cases diagnosed at stages 3 or
4: breast cancer (16.34% stage 3 or 4), colorectal cancer (38.28%), and
endometrial cancer (9.57%).
When compared to the entire study sample, a higher percentage of cases that
were identified as appropriate for referral were diagnosed at or under the age of
50 (31.08% vs. 17.24% in the entire study sample) given that young age is a
criteria for referral for both breast and endometrial cancers. The majority of the
cases included in this analysis were from individuals who identified as being
white, both in the entire data set (92.17%) and in those appropriate for referral
(91.52%).
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Table 3: Characteristics of Cancer Cases Appropriate for Genetic Referral by
Cancer Type
Breast
(n=4229)
Age at dx

Ovarian/FT
(n=1057)

Colorectal
(n=9815)

Endometrial
(n=376)

Total
(n=15477)

N

%

N

%

N

%

N

%

N

%

< 35 years

225

5.32%

21

1.99%

98

1.00%

46

12.23%

390

2.52%

35-50 years

2919

69.02%

156

14.76%

1015

10.34%

330

87.77%

4420

28.56%

51-65 years

619

14.64%

385

36.42%

3269

33.31%

n/a

n/a

4273

27.61%

> 65 years

466

11.02%

495

46.83%

5433

55.35%

n/a

n/a

6394

41.31%

Sex
Male

84

1.99%

0

0.00%

5107

52.03%

0

0.00%

5191

33.54%

4145

98.01%

1057

100.00%

4708

47.97%

376

100.00%

10286

66.46%

White

3764

89.00%

1010

95.55%

9033

92.03%

358

95.21%

14165

91.52%

Black

403

9.53%

40

3.78%

669

6.82%

15

3.99%

1127

7.28%

Other

33

0.78%

6

0.57%

49

0.50%

1

0.27%

89

0.58%

Unknown

29

0.69%

1

0.09%

64

0.65%

2

0.53%

96

0.62%

Stage ≤ 2

3460

81.82%

299

28.29%

5272

53.71%

306

81.38%

9337

60.33%

Stage 3 or 4

691

16.34%

656

62.06%

3757

38.28%

36

9.57%

5140

33.21%

Other/Unknown

78

1.84%

102

9.65%

786

8.01%

34

9.04%

1000

6.46%

Appalachian

1020

24.12%

307

29.04%

3011

30.68%

121

32.18%

4459

28.81%

Non-Appalachian

3209

75.88%

750

70.96%

6804

69.32%

255

67.82%

11018

71.19%

Alive

3752

88.72%

551

52.13%

6066

61.80%

354

94.15%

10723

69.28%

Deceased

477

11.28%

506

47.87%

3749

38.20%

22

5.85%

4754

30.72%

Female
Race

Cancer Stage

Appalachia County

Vital Status

When comparing the cases that met criteria for referral to those cases that
did not meet criteria, cases identified as being appropriate for referral had a
higher proportion of individuals who were identified as black than in those cases
that did not meet criteria for referral (7.37% in the referred group vs. 6.31% in the
non-referred group, χ2=12.025, p=0.0005). Cases that were identified as
appropriate for referral were more likely to be stage 3 or 4 cancers (n=5140,
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33.21%) than all cancers analyzed in the study (n=6853, 24.38%). Cases
appropriate for referral to genetic services were statistically significantly more
likely to be stage 3 or 4 cancers than cases that were determined to not be
appropriate for referral (35.50% in the referred group vs. 14.17% in the nonreferred group, χ2=1567.35, p<0.0001). Individuals represented by the cases
included in the referral data set were slightly more likely to be from Appalachian
counties than in the data set as a whole (28.81% of referrals vs. 27.98% of all
cases) and were statistically significantly more likely to be from Appalachian
counties than those cases not identified as appropriate for referral (28.81% in the
referred group vs. 26.96% in the non-referred group, χ2=11.88, p=0.0006).
Individuals represented by the cases in the referral data set were less likely to be
living (69.28%) than those determined to be not appropriate for referral (84.75%)
(p<0.0001), which could be in part due to the fact that cases in the referral data
set were more likely to be later stage cancers (stage 3 or 4). These results are
summarized in Table 4.
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Table 4: Comparison of Cases Appropriate for Referral to Cases Not
Appropriate for Referral
Referral

Age at dx
< 35 years
35-50 years
51-65 years
> 65 years
Sex
Male
Female
Race*
White
Black
Other
Unknown
Cancer Stage*
Stage ≤ 2
Stage 3 or 4
Other\Unknown
Appalachia County*
Appalachian
NonAppalachian
Vital Status*
Alive
Deceased

Total
n=28,109

No
n=12,632

Yes
n=15,477

403 (1.43%)
4444(15.81%)
10654(37.90%)
12608 (44.85%)

13 (0.10%)
24 (0.19%)
6381 (50.51%)
6214 (49.19%)

390(2.52%)
4420 (28.56%)
4273 (27.61%)
6394 (41.31%)

5191 (18.47%)
22918(81.53%)

0 (0.0%)
12632 (100.0%)

5191 (33.54%)
10286 (66.46%)

25907 (92.17%)
1918 (6.82%)
148 (0.53%)
136 (0.48%)

11742 (92.95%)
791 (6.26%)
59 (0.47%)
40 (0.32%)

14165 (91.52%)
1127 (7.28%)
89 (0.58%)
96 (0.62%)

19716 (70.14%)
6853 (24.38%)

10379 (82.16%)
1713 (13.56%)

9337 (60.33%)
5140 (33.21%)

1540 (5.48%)

540 (4.27%)

1000 (6.46%)

7864 (27.98%)

3405 (26.96%)

4459 (28.81%)

20245 (72.02%)

9227 (73.04%)

11018 (71.19%)

21429 (76.24%)
6680 (23.76%)

10706 (84.75%)
1926 (15.25%)

10723 (69.28%)
4754 (30.72%)

In order to better characterize the annual need for cancer genetic counseling
services for individuals with newly diagnosed cases of breast, ovarian, fallopian
tube, colorectal and endometrial cancers across the state of Kentucky, the most
recent year of data (2012) was used to look at distribution of cases appropriate
for genetic referral among Kentucky counties (n=3966). Of the 120 Kentucky
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counties, all counties had at least 1 individual diagnosed with one of the cancers
examined in this study who met criteria for referral to genetic counseling. The
five counties with the highest number of cases identified as appropriate for
referral in 2012 were 1) Jefferson County (n=729, 18.38% of appropriate cases
identified in the state), 2) Fayette County (n=255, 6.43%), 3) Kenton County
(n=108, 2.72%), 4) Hardin County (n=106, 2.67%) and 5) Boone County (n=100,
2.52%), which is expected as these five counties are included in the six highest
populated counties in the state. Of these 5 counties, 3 (Jefferson, Fayette, and
Kenton) have full time genetic counseling services available in the county, Boone
county has services available in a bordering county, and Hardin County has
services available through outreach programs. Overall, residents in 12/120
counties (10%) have access to genetic counseling services in their county. A
summary of cases by county is included in Figure 1.
Appropriate cases for referral in 2012 were also examined by area
development district (ADD). The state of Kentucky is made up of 15 ADD’s,
which are planning and developing districts made up of multiple counties19. The
counties in each ADD work together to attain economic growth, improve the
quality of life, and provide services to their residents. The Kentuckiana Regional
Planning and Development Agency (KIPDA) has the highest number of cancer
cases identified as appropriate for referral to genetic counseling services (n=933)
and is made up of Jefferson, Bullitt, Oldham, Trimble, Henry, Shelby and
Spencer Counties. The Bluegrass ADD contains the second highest number of
cases appropriate for referral (n=699) and is made up of Anderson, Franklin,
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Figure 1: Appropriate Referrals by County

Woodford, Mercer, Boyle, Lincoln, Garrard, Jessamine, Fayette, Scott, Harrison,
Bourbon, Nicholas, Clark, Madison, Powell, and Estill counties. Of the 15 ADD’s
in Kentucky, only 3 have full time, on-site genetic counselors providing cancer
genetic counseling services (KIPDA, Bluegrass and Northern Kentucky) with an
additional 6 ADD’s having cancer genetic counseling services available via
outreach clinics or telemedicine (Cumberland Valley, Gateway, Green River,
Kentucky River, Lincoln Trail, and Pennyrile). Of individuals identified in this
study as being appropriate for referral for cancer genetic counseling services,
75% (2973/3966) can access these services with a genetic counselor in their
ADD. However, even in ADD’s with a genetic counselor, some patients may
have to drive an hour or more to access services. The number of appropriate
cases for referral to genetic services in each ADD are shown in Figure 2.
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Figure 2: Appropriate Referrals by Area Development District

D. DISCUSSION
This study represents the first analysis of Kentucky Cancer Registry data for
identifying cases that would be appropriate for referral to genetic services due to
being at risk for HBOC or LS. The study shows that over the four year period
between 2009-2012, 15,477 (55.06%) of the 28,109 cases of breast, ovarian,
fallopian tube, colorectal or endometrial cancer in Kentucky were appropriate for
referral to genetic services based on meeting at least one of the NCCN, EGAPP,
and ABGC/NSGC criteria examined by this study.
Analysis of the Kentucky Cancer Registry data shows that cancer cases
appropriate for referral to genetic services had overrepresentation of late stage
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(stage 3 and 4) cancers and cancer deaths when compared to the breast,
ovarian, fallopian tube, colorectal and endometrial cancers that were not
appropriate for referral during the study time period. In cases appropriate for
referral to genetic services, 33.21% were late stage cancers, and 30.72% of
cases were from individuals now deceased. Increasing the number of individuals
referred for genetic services in the state of Kentucky and then focusing on testing
the relatives of patients with positive genetic test results through cascade
screening has the potential to result in more individuals being identified as having
HBOC and LS before cancer develops. These Individuals can be offered
increased screening and preventive services to either prevent a cancer from
developing or improve the chances that a cancer is diagnosed at the earliest
possible stage if it were to form. Based on the information from this study, this
could subsequently contribute to a decrease in late stage cancers and cancer
deaths in Kentucky. A public health focus on increasing genetic counseling and
testing services for individuals at risk for hereditary cancer syndromes in
Kentucky would not only contribute to the achievement of national goals in public
health genetics, such as the Healthy People 2020 goals, but also to state health
goals. Recently, Kentucky’s Governor released the KY Health Now goals, which
call for a reduction in cancer deaths in the state by 10% by 201920. While
individuals with a hereditary cancer syndrome such as HBOC and LS will make
up a small percentage of all cancers diagnosed, identifying them offers an
opportunity for primary prevention in those at the highest risk to develop cancer.
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This study also showed that cancer cases identified as appropriate for referral
to genetic services had a higher proportion of individuals identified as black
(7.28%) than those cases determined not to be appropriate for referral (6.26%,
p=0.0005); however, it is important to note that the vast majority of the cases in
both groups were individuals identified as white. This finding is likely influenced
by a number of factors including that African American women are more likely to
be diagnosed with triple negative breast cancer, which is one of the criteria for a
case to be a referral. Furthermore, African American women in Kentucky have a
higher incidence of invasive breast cancer diagnosis than white women in
Kentucky21. There was also a higher proportion of individuals living in
Appalachian-designated counties in the cases appropriate for referral (28.81%)
than in those cases determined not to be appropriate for referral (26.69%,
p=0.0006). Although these differences between referral and non-referral cases
are small, but significant, it is important to consider these differences given that
these represent two underserved populations. These results can provide
important information to genetics providers and public health departments in the
state to further validate the development of programs to increase patient
identification and referrals. Previous studies have often shown disparities in the
access to and use of genetic services by minority groups, specifically African
Americans22–24. Few studies have been done to look at genetic counseling in the
Appalachian population, but a 2007 study did find that living in an Appalachian
county was not associated with intent to seek cancer genetic services 25.
However, individuals in Appalachian counties likely face a number of barriers to
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accessing healthcare services such as cost, transportation, child care, obtaining
time off from work, lower education levels, etc. that could hinder their chances of
obtaining genetic services. Furthermore, only 4 of the 54 Kentucky counties
designated as Appalachian counties by the Appalachian Regional Commission
(Madison, Whitley, Rowan, and Perry counties) have genetic counseling services
through outreach or telemedicine. Given that individuals from Appalachian
counties were overrepresented in the cases appropriate for referral and currently
have limited access to genetic counseling services, public health departments
should look to expand access to genetic counseling in these areas of Kentucky.
While the differences between groups may change with the use of additional
criteria for case referral that are not included in this study, additional criteria
would only increase cases where individuals were African American or living in
Appalachian counties. This would further support the need for expanding genetic
counseling services to underserved populations.
The identification and referral of patients diagnosed with cancer who are at
risk for HBOC and LS is important for determining the best plan for additional
cancer screening and preventive measures in the future, and may also have
implications for treatment of an individual’s current cancer diagnosis.
Additionally, relatives of individuals who are identified as having HBOC or LS are
also at risk for having the condition and its associated increased risk for cancer.
However, many patients and their relatives who are at risk for HBOC and LS
remain unaware of their risk and are not appropriately referred to genetic
services by their medical providers. One recent study found that physicians
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correctly identified only 41% of women at high risk for HBOC and referred them
for genetic counseling and testing26. A study conducted in Michigan showed that
in 2012 only an estimated 23.4% of women who had a relative diagnosed with
breast cancer at or under age 50 had a family member who had undergone
genetic counseling, and this number was lower for women with a family history of
ovarian cancer, where only 15.9% reported that a family member had had
genetic counseling27. Individuals who are not appropriately referred for genetic
services represent a missed opportunity to provide preventive services to those
who are at the highest risk for a future diagnosis of cancer.
The CDC has proposed methods for state and local health departments to
use to increase the identification of individuals at risk for HBOC and LS in their
states28. One method of improving identification is through bidirectional cancer
registry reporting. The analysis and results of this study will provide helpful
information for Kentucky public health departments and genetics providers for
taking the first steps towards public health genetics program planning.
One major obstacle to implementing a population based screening program
such as bi-directional reporting with the cancer registry is having the genetics
professional capacity to handle the resulting case load. Our results indicate that
a significant number of individuals per year would be appropriate for genetic
services. In 2012, the most recent year in the study, 3966 cases were identified
by this analysis as appropriate for referral. If even half of these individuals who
were identified as meeting criteria for genetic services would see a genetic
counselor, this would be an estimated 1983 patients newly diagnosed with
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cancer each year who would utilize genetic counseling based on the 2012 data
from this study. Based on the National Society of Genetic Counselors (NSGC)
2012 Professional Status Survey, genetic counselors specializing in cancer see
an average of 6 new patients per week29. In order to cover just the patients
identified in this study for genetic counseling services, 6.4 full time cancer genetic
counselors would need to be employed in the state. If we estimate a 10% rate
for positive genetic test results among these patients, this would result in
approximately 198 new patients each year identified with HBOC or LS.
In addition to the index cases identified through bidirectional cancer registry
reporting or another population-based program, family members of those index
cases who have positive test results will also need access to cancer genetic
counseling services. A Kentucky study that looked at automatic referral for
certain groups of patients diagnosed with breast and ovarian cancer in one
healthcare system found that for each index patient found to have a BRCA1 or
BRCA2 mutation, there was an average of 5.6 first degree relatives who would
have a 50% risk for also carrying the mutation30. Similarly, a study looking at
relatives of index patients who were identified as having LS reported that 249
relatives of 33 index patients identified with LS underwent testing, or over 7
relatives per index patient31. In that study, 109 of these relatives tested positive
(greater than 3 relatives per index case), and cascade screening could be used
to continue to systematically screen additional relatives. Considering the 198
newly diagnosed cancer patients per year estimated to be found to have HBOC
and LS using the criteria examined in this study, 1109 first degree relatives at
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50% risk would be identified (estimating 5.6 first degree relatives per index case),
many of whom will be unaffected carriers of HBOC or LS and unaware that they
may have a significantly increased risk for cancer.
In order to also provide services to these at-risk, first degree family members,
3.6 additional full time genetic counselors would need to be employed, for a total
of 10 cancer genetic counselors just to provide services to individuals newly
diagnosed with breast, ovarian, fallopian tube, colorectal and endometrial
cancers each year and their first degree relatives. This model to estimate the
number of genetic counselors needed to provide services as a result of a
bidirectional cancer registry reporting program is summarized in Figure 3.
The number of genetic counselors needed to provide cancer genetic
counseling in this state will likely far exceed the 10 estimated by this analysis due
to the limitations of this data analysis resulting in an underestimate of the
individuals in Kentucky appropriate for cancer genetic services each year. In
addition to patient care, genetic counselors would likely also need to increase
participation in provider and public education in order to prepare for a population
screening program. Genetic counselors specializing in cancer also often see
patients for other hereditary cancer syndromes as well as patients with concerns
other than hereditary cancer. The “Find a Counselor” search function on the
NSGC website and personal communications with genetic counselors in
Kentucky indicate that there are 10.5 genetic counselors currently providing
cancer genetic counseling services in the state

32.

These genetic counselors are

located in the three major cities in Kentucky: Louisville, Lexington, and
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Covington and provide outreach services to other areas (clinics and outreach
summarized in Appendix A). If population based public health genetics programs
for the identification of individuals with HBOC and LS are to be successfully
implemented in the state of Kentucky, it is imperative to support the growth of
cancer genetic counselors and cancer genetic counseling clinics in the state.
Analysis of cases by county and ADD indicate that there is a need for cancer
genetic counseling services throughout the state. Currently, only 10% of
Kentucky counties have cancer genetic counseling services available within the
county. However, when larger ADD’s are considered, residents in 9 of the 15
districts encompassing 75% of cases meeting guidelines for referral, have
access to these services. If a population based program were to be
implemented, it would be important for the Kentucky Department for Public
Health and local health departments in the 6 ADDs without access to cancer
genetic counseling services to determine the best way to offer services in these
areas. Applying the same model for estimating the number of patients and their
first degree relatives (FDRs) who would access genetic counseling services as
outlined in Figure 3 for the individual ADDs can help public health leaders identify
the best placement of additional genetic counselors.

Figure 3: Model for Estimating Genetic Counseling Workforce Needed in KY to
Provide Services to Patients Identified Through Bidirectional Screening Program
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1983

198

1109

3092

10

• 3966 cases identified in 2012 appropriate for referral
• Estimate half of appropriate patients elect to pursue
genetic services

• Estimate a 10% positive rate for HBOC or LS in referred
patients

• Estimate 5.6 1st degree relatives per positive patient who
will need genetic services

• Estimated number of patients each year who will need
genetic services as a result of a public health program
aimed at increasing identification of at-risk individuals
(1109 + 1983)
• Cancer genetic counselors see an average of 6 patients
per week (312 patients per year)
• 10 genetic counselors would be required to see these
patients

The number of estimated patients and FDRs that would present annually in each
ADD are summarized in Table 5. Based on this information, an additional 1.17
full time genetic counselors in Barren River and Lake Cumberland ADDs would
be able to cover the patients identified through the proposed population based
program, which improve overall access to services in Kentucky because these
are the ADDs that currently do not have genetic counseling services with the
largest number of appropriate cases for genetics referral. Furthermore, they are
located in the southern part of the state where services are sparse. Although
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there are fewer cases in the ADDs in the eastern part of Kentucky, the ADDs
Fivco, Big Sandy, and/or Buffalo Trace would also benefit from the addition of a
genetic counselor to expand services to this underserved area. While these
genetic counselors would cover the patients identified through a bidirectional
cancer registry screening program, additional patients who meet national
guidelines not included in this study would also be appropriate for referral, which
further increases the need for genetic counseling in these areas. Furthermore,
given that over 40% of Kentucky residents live in rural areas, alternative methods
of delivery of services, such as telemedicine, should be considered across the
state33. Currently, several genetic counseling centers in Kentucky are offering
telemedicine services, which could be used as models for setting up additional
services in the state.
While bidirectional cancer registry reporting is an important method for
identifying index cases who have been diagnosed with cancer in families with
HBOC and LS, it will not identify all individuals who meet national guidelines for
referral to genetic counseling and/or testing1. The major limitation of this study is
that it likely provides a conservative estimate of the number of individuals newly
diagnosed with these cancers who would be appropriate for a genetics referral
for evaluation of HBOC or LS. This is due to this data not including individuals
who would meet other criteria for referral to genetic services, including having a
known mutation in the family, being diagnosed with multiple primary cancers,
being of Ashkenazi Jewish heritage, or having a significant family history of
cancer 11. The analysis also did not look at individuals with cancers other than
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breast, ovarian, fallopian tube, colorectal, and endometrial cancer that are
associated with HBOC and LS. Additional cancers that are associated with these
syndromes include pancreatic, prostate, stomach, small bowel, urinary tract,
hepatobiliary tract, brain, and other cancers4,34.
Table 5: Annual Estimated Patients & First Degree Relatives (FDR) by ADD
Referral
Cases 2012

Estimated
Annual Pts &
FDR*

# GCs
Needed**

ADD
Barren River
243
190
0.61
Big Sandy
144
112
0.36
Bluegrass
699
545
1.75
Buffalo Trace
68
53
0.17
Cumberland Valley
176
137
0.44
Fivco
117
91
0.29
Gateway
83
65
0.21
Green River
180
140
0.45
Kentucky River
142
111
0.36
KIPDA
933
728
2.33
Lake Cumberland
223
174
0.56
Lincoln Trail
293
229
0.73
Northern Kentucky
309
241
0.77
Pennyrile
158
123
0.39
Purchase
198
154
0.49
*Using model outlined in this paper
Estimated cases & FDR = ((# cases)(.5) + (#cases)(.5)(.1)(5.6))
**Using model outlined in this paper
GCs = (Estimated cases & FDR)/312

Additional groups who were not included in this study are individuals with a
significant family history of cancer who have not been diagnosed with cancer
themselves, individuals without cancer with a known mutation in the family, and
individuals who were diagnosed with breast, ovarian, fallopian tube, colorectal or
endometrial cancer prior to 2009 or after 2012 who meet criteria for referral to
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genetic services but were never offered these services. The latter of these
groups likely represents a significant number of individuals who are at risk for
HBOC or LS in Kentucky, given that this study shows that an average of 3869
patients each year are appropriate for referral using a subset of national
guidelines. A recent study of one Kentucky hospital’s cancer center screened
patient appointment lists to identify women who had been diagnosed with breast
cancer under age 50 or ovarian cancer at any age who had not previously been
referred for genetic counseling services30. In one year, 521 patients were
identified for referral, with a mean number of years since diagnosis of 5.3 years
for women with breast cancer and 2.7 years for women with ovarian cancer 30.
This study illustrates that in addition to the women identified in this data analysis
who have new diagnoses of breast or ovarian cancer, a significant number of
individuals with past diagnoses are also appropriate for referral to genetic
services but have not received them. This study was conducted at a cancer
center with an established genetic counseling program, and it is posited that
hospitals and physician offices that do not employ full time genetic counselors
would have a higher percentage of patients appropriate for a genetic risk
assessment who have not been referred.
The EGAPP recommendations for offering testing for LS to every patient
diagnosed with colorectal cancer were released in January 2009 7. Prior to this
recommendation, standard practice for identifying patients for referral to genetic
services for LS involved the use of clinical criteria that relied on family history
information. However, as many as 28% of patients with LS would not meet the
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previously established clinical criteria for patient identification31. Even after the
publication of the EGAPP guidelines, uptake of universal screening programs of
colorectal cancers for LS has been slow. A study surveying a sample of National
Cancer Institute-designated Comprehensive Cancer Centers, Community
Hospital Cancer Programs, and Community Hospital Comprehensive Cancer
Programs found that 15.9% of responding institutions (11/69) were performing
universal IHC screening on colorectal tumors in 200935. A later study that
surveyed genetic counselors working in a cancer setting found that 27.4% of
respondents (29/106) indicated that their institution was universally screening
colorectal tumors for LS as of 201136. Barriers to universal IHC screening
implementation were identified and included cost, assembling stakeholders, and
obtaining approval from appropriate medical staff 36. This delayed implementation
of screening programs based on the EGAPP guidelines indicate that all
individuals with colorectal cancer are not currently being offered screening and/or
testing for LS in Kentucky and that there are likely significant numbers of patients
diagnosed before the time period examined in this study who would be still be
appropriate for referral for genetic services to discuss options for evaluation.
Individuals who are at risk for hereditary cancer syndromes other than HBOC
and LS would also benefit from referral to genetic services, thus further
increasing the need for genetic services above what is discussed in this study.
Finally, while bidirectional cancer registry reporting will identify index cases,
cascade screening to identify at-risk family members will need to be conducted
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through other methods. Thus, it is important that providers remain vigilant in
identifying patients via the ascertainment of a detailed family health history1.
Another limitation of this study is that Kentucky Cancer Registry data can only
provide information on who is appropriate for referral to genetic services, but not
who has been offered or pursued these services. In fact, there is no state-wide
data source to obtain this information. Rather, it would have to be collected from
individual institutions.
In conclusion, this study shows that there is a significant, ongoing need for
cancer genetic counseling services in the state of Kentucky. At this time, the
genetic counselors employed in Kentucky would likely not able to effectively see
the volume of patients that would result from such a program. Thus,
simultaneous attention needs to be given to growing the genetic counseling
workforce and developing public health genetics programs for HBOC and LS.
Through these programs, Kentucky and other states can ensure that the
residents are obtaining appropriate referrals to cancer genetic counseling that
could prove life-saving to themselves and their relatives.
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CHAPTER 3:
PAPER 2: UTILIZING MEDICAID CLAIMS DATA TO ASSESS THE
USE OF GENETIC TESTING FOR HEREDITARY BREAST AND
OVARIAN CANCER SYNDROME IN KENTUCKY AND
CHARACTERISTICS THAT INFLUENCE GENETIC TESTING
COMPLETION
A. INTRODUCTION
B. MATERIALS AND METHODS
C. RESULTS
D. DISCUSSION

A. INTRODUCTION
Breast cancer is the most common cancer diagnosed in women in the U.S.
and the second leading cause of cancer death in women1. Although far less
common, ovarian cancer is the fifth leading cause of cancer death in women 1. A
small, but significant subset of breast and ovarian cancers are due to Hereditary
Breast and Ovarian Cancer (HBOC) syndrome, which is a genetic condition that,
most often, is associated with mutations in the BRCA1 and BRCA2 genes.
HBOC due to BRCA1 and BRCA2 mutations causes increased lifetime risks for
breast (up to 90%), ovarian (up to 62%), and other cancers2. It is estimated that
approximately 5% of female breast cancer (9.5% of breast cancers diagnosed
under age 50), 25% or more of male breast cancers, and up to 18% of ovarian
cancers are due to HBOC 3–6.
Individuals who have been diagnosed with cancer and found to have a
BRCA1 or BRCA2 mutation are at increased risk for developing a second
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cancer. Results of genetic testing can provide important information for the
surgical management of high risk women newly diagnosed with breast cancer7–
11.

Genetic testing also has important implications for the medical treatment of

cancer, especially with the recent FDA approval of Lynparza (olaparib) for the
treatment of women with a BRCA1 or BRCA2 mutation and ovarian cancer12.
Furthermore, it is preferable to complete BRCA1 and BRCA2 genetic testing in a
family first in an individual who has already been diagnosed with cancer13. The
American Society of Clinical Oncology recommends that patients diagnosed
with cancer who meet specific criteria be offered genetic testing for hereditary
cancer syndromes including HBOC, and the Commission on Cancer requires
that genetic counseling and testing services be available to patients either onsite or through referral as part of their accreditation program 14,15.
After an index case of HBOC is identified in a family, other relatives can
typically be identified who are at risk for carrying the same genetic mutation and
increased risk for cancer. Testing can then systematically be offered to these
relatives to identify high-risk individuals who would benefit from increased
screening and prevention for breast and ovarian cancer. Interventions available
for individuals found to have a BRCA1 or BRCA2 mutation include prophylactic
removal of the breasts and/or ovaries, earlier and additional screening for breast
cancer, and taking medications that can reduce the risk of cancer2,4. These
interventions have been shown to be effective at reducing cancer risk and/or
diagnosing a cancer earlier in individuals with BRCA1 and BRCA2 associated
HBOC.
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There is extensive literature on disparities in the referral of patients for genetic
counseling and/or testing and the uptake of genetic testing, which has been a
concern since testing was first implemented. Many of these studies have
focused on racial disparities in genetic testing for HBOC. An early study by
Armstrong, et al. found that Caucasian women had 4.1 times the odds of
undergoing genetic counseling for BRCA1 and BRCA2 than non-Caucasian
women16. A case-control study of women with a family history of breast or
ovarian cancer undergoing genetic counseling between 1999 and 2003
determined that African American women were significantly less likely to have
genetic counseling than Caucasian women even after controlling for other
factors that affect uptake (adjusted OR=0.28, 95% CI 0.09-0.89)17. However, a
study of women referred for genetic counseling between 2001 and 2008 found
no difference in the uptake of genetic testing by race among individuals who
received genetic counseling18. Continued documentation of racial disparities in
access to genetic counseling for hereditary cancer syndromes led Hall et al. to
state that, “Increasing testing access and volume in racial/ethnic minority and
underserved populations must be a national priority if mounting disparities in
genetic testing utility and utilization are to be eliminated.”19 Other patient sociodemographic factors found to influence uptake of genetic counseling or testing
include age, referral source, marital status, increased breast cancer risk, and
knowledge of genetics16,20,21.
Provider barriers can also affect whether a patient appropriate for genetic
counseling and/or testing is referred for genetic services. Awareness of genetic
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services has been found to be essential to provider referral, and many studies
have called for increased education of physicians about genetic counseling and
testing for hereditary cancer22–24. One study of a national sample of primary and
tertiary care physicians found that referrals were highest for patients who
initiated the conversation about genetic risk for breast and ovarian cancer
themselves (OR 5.52; 95% CI, 3.97-7.67)22. Concerns about insurance
coverage for testing and the fear of genetic discrimination have also traditionally
impacted physician referral as illustrated in multiple studies that were conducted
before and after the Genetic Information Nondiscrimination Act (GINA) was
passed in May 200822–25.
Early studies of the referral and uptake of BRCA1 and BRCA2 genetic testing
indicated that lack of provider knowledge and lack of clinical guidelines for
referring patients were barriers to patients receiving this testing23,24,26. More
recently, several organizations have published evidence-based guidelines for
identifying individuals appropriate for genetic risk assessment, counseling, and
testing. The National Comprehensive Cancer Network (NCCN) has issued
guidelines for identifying individuals diagnosed with breast, ovarian, and
fallopian tube cancers who are appropriate candidates for genetic testing 2. The
American College of Medical Genetics (ACMG) and National Society of Genetic
Counselors (NSGC) have issued joint guidelines for identifying individuals with a
variety of hereditary cancer syndromes, including HBOC, and the U.S.
Preventive Services Task Force (USPSTF) published guidelines specifically for
identifying unaffected, at-risk women appropriate for genetic counseling27.
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However, many individuals with HBOC are not appropriately referred and
remain undiagnosed despite these national guidelines for patient
identification25,28,29.
Genetic testing for HBOC has been identified by the Centers for Disease
Control and Prevention (CDC) as a Tier 1 Genomic Application based on
analytic validity, clinical validity, clinical utility and existing evidence-based
guidelines indicating that the use or test is ready for population-based
implementation30,31. Recently, the CDC has released a toolkit for local and state
health departments to help these entities implement programs for the education,
identification, and screening of individuals at increased risk for HBOC and other
Tier 1 Genomic disorders 32. As states begin the process of developing and
implementing these programs, special attention should be paid to disparities in
genetic counseling and testing specific to the state. While previous studies
certainly provide a starting point for considering and addressing disparities, the
majority of these studies looking at disparities in genetic counseling and testing
for HBOC based on patient socio-demographic factors have been institution
specific, and studies of provider-perceived barriers have largely been conducted
through institutional or national surveys22–24,26.
Utilizing data already being collected by states can be helpful in both
assessing need for genetic counseling and testing services and in identifying
state-specific disparities. In this study, Kentucky Medicaid Claims data is
utilized to identify genetic testing disparities in an already underserved
population. The use of this data set allows for assessment of disparities when
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insurance coverage is not an issue as Kentucky Medicaid has covered genetic
testing in full for patients meeting clinical criteria for HBOC over the time period
included in this secondary data analysis. Furthermore, genetic testing of the
BRCA1 and BRCA2 genes has been available commercially in the U.S. for
nearly 20 years. This testing had been performed exclusively by Myriad
Genetics, Inc. until June 2013 when the Supreme Court decision of Association
of Molecular Pathology, et al v. Myriad Genetics, Inc., et al. invalidated some of
the patents held by Myriad on the BRCA1 and BRCA2 genes, prompting other
laboratories to begin offering testing33. A single laboratory offering this testing
simplifies the search for individuals who have undergone testing in the Medicaid
Claims data set. Utilizing a secondary data source also represents a costeffective way for an initial analysis to be completed in a state, such as Kentucky,
where there is no funding or dedicated staff for public health genetics and
genomics outside of newborn screening.
The aims of the current study are to 1) determine how many individuals with
Kentucky Medicaid diagnosed with breast, ovarian, and fallopian tube cancer
who were appropriate for genetic counseling and testing for HBOC received
genetic testing; and 2) determine the socio-demographic and provider factors
that predict receipt of genetic testing. Information about the factors that predict
whether a particular patient receives genetic testing can then be used by public
health and genetics professionals to begin to address the particular disparities in
access to genetic counseling and testing services present in Kentucky. To our
knowledge, this is the first study utilizing state Medicaid data to conduct a needs
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assessment for cancer genetic counseling and testing services and identify
state-specific disparities in access to these services.
B. METHODS
This study consists of a secondary data analysis of Kentucky Medicaid data
for individuals diagnosed with breast (including male breast), ovarian, or fallopian
tube cancer from 2009-2012. Data were obtained from the Kentucky Medicaid
Claims Database using ICD-9 codes corresponding to these diagnoses of
cancer. ICD-9 codes included 174.* (malignant neoplasm of female breast),
175.* (malignant neoplasm of male breast), 183.0 (malignant neoplasm of ovary),
and 183.2 (malignant neoplasm of fallopian tube). The data set was obtained
after University of Kentucky and the Kentucky Cabinet for Health and Family
Services IRB approval.
The following NCCN criteria for referral to genetic services for HBOC were
used to determine which individuals included in the Kentucky Medicaid data set
would be appropriate candidates for referral 2:


Women diagnosed with breast cancer ≤ 50y



Women diagnosed with ovarian or fallopian tube cancer



Men diagnosed with breast cancer at any age

Given that this is a cross-sectional data set, information was not available on
the age at diagnosis with cancer. Thus, women diagnosed with breast cancer
included in the data set were considered appropriate for genetic testing if their
youngest age at the time of a claim in the database was age 50 or younger. All
individuals diagnosed with ovarian, fallopian tube, and male breast cancer were
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considered appropriate for referral. CPT codes that designate genetic testing
were used to determine those individuals in the subset of records identified as
being appropriate for genetic counseling and/or testing who actually were tested.
These CPT codes included: 83891 (isolation or extraction of highly purified
nucleic acid), 83898 (amplification of patient nucleic acid), 83904 (mutation
identification by sequencing), 83909 (separation by high resolution technique),
and 83912 (interpretation and report). In 2012, additional CPT codes were
introduced for genetic testing of the BRCA1 and BRCA2 genes, including: 81211
(BRCA1, BRCA2 gene analysis; full sequence analysis and common
duplication/deletion variants in BRCA1), 81212 (BRCA1, BRCA2 gene analysis;
185delAG, 5385insC, 6174delT variants (the three common mutations found in
the Ashkenazi Jewish population)), 81213 (BRCA1, BRCA2 gene analysis;
uncommon duplication/deletion variants), 81214 (BRCA1 gene analysis; full
sequence analysis and common duplication/deletion variants), 81215 (BRCA1
gene analysis; known familial variant), 81216 (BRCA2 gene analysis; full
sequence analysis), and 81217 (BRCA2 gene analysis; known familial variant).
These were also used to determine individuals who had undergone genetic
testing in 2012. Although Healthcare Common Procedure Coding System
(HCPCS) codes were introduced for genetic testing during the time period
included in this secondary data analysis, they did not appear in the data set and
as a result were not used to identify individuals undergoing genetic testing.
Variables included in the data set received from the Kentucky Medicaid
Claims database and utilized in this study were: Medicaid ID number, age at
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claim, gender, ethnicity, patient geographical coordinates (latitude/longitude),
billing provider, place of service, category of service, provider specialty,
procedure codes, date of claim, ICD-9 Codes, patient survival, and presence of
CPT codes for genetic testing (83891, 83898, 83904, 83909, 83912, 81211,
81213). The Medicaid claims data set contained multiple entries per Medicaid
recipient, and information was condensed to create one entry per individual
meeting the above stated criteria for genetic testing. For individuals who had
conflicting information coded into the database for fixed characteristics, such as
race, sex, and ethnicity, the description that occurred most commonly in the data
set was used and applied to the unique entry for that individual. For
demographic information that was claim dependent such as including whether
services were received in an Appalachian county, final entries were coded based
on where the majority of services were received. Age was determined using the
age at claim for the earliest claim in the database for any given individual. Cancer
type was determined using ICD-9 codes included with each claim. The database
contained the first four ICD-9 codes per claim, and cancer type was determined
first by the primary diagnosis code, and then by secondary diagnosis codes if
one of the ICD-9 codes examined in this study was not present. Data cleaning
identified several individuals with both breast and ovarian (or fallopian tube)
cancers, and the unique entry for those Medicaid ID numbers were coded based
on the first cancer to appear in the database.
Basic descriptive statistics are reported for the data subset of individuals
determined to be appropriate for referral to genetic services. Independent
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sample t-test (for continuous variables) and Chi-square tests (for categorical
variables) were used to determine differences between individuals who did and
did not receive genetic testing. Logistic regression was then performed to
evaluate which demographic and provider variables were associated with the
outcome variable of whether an individual received genetic testing while
controlling for other variables in the model. All independent variables of interest
were included in the first model, and the final model was obtained by excluding
some variables that were not significant. Breslow-Day tests were used to
determine possible variable interactions.
Multiple diagnostics were assessed for the final model including
convergence criterion, the likelihood ratio to determine if the overall model was
significant, Hosmer and Lemeshow Goodness of fit test to determine if the fitted
model was an adequate fit, and the r-square value.
The locations of cancer genetic counseling services were obtained
through key informant interviews with genetic counselors in the state of
Kentucky. All statistical analyses were completed using SAS v.9.3 and R version
3.1.3.
C. RESULTS
A total of 3144 unique individuals included in the Kentucky Medicaid Claims
Database between 2009 and 2012 were identified as meeting criteria for genetic
testing for HBOC based on the criteria outlined previously. Of these individuals,
1849 had female breast cancer and a claim in the database at or under age 50.
There were 74 individuals diagnosed with male breast cancers included in the
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data set and 1221 individuals diagnosed with ovarian or fallopian tube cancers.
Of note, 34 individuals in the data set had ICD-9 codes for both female breast
and ovarian/fallopian tube cancer. For the purpose of this study, which utilized
only one observation per individual included in the database, these individuals
had their cancer type classified based on which diagnosis appeared on the
earliest claim. Of these 3411 unique individuals, 241 (7.7%) had a claim for
genetic testing between 2009 and 2012. These results are summarized in Table
1.
Table 1: Appropriate Referrals and Genetic Testing by Cancer Type

Breast
(Female)
Breast (Male)
Ovarian/FT

Appropriate
Referral
(n=3144)

Genetic Testing
(n=241)

1849
74
1221

226 (12.2%)
0 (0%)
15 (1.2%)

Given that genetic testing is often associated with multiple CPT codes for one
test, the 241 individuals who had genetic testing claims between 2009 and 2012
had a total of 1402 claims with one of the CPT codes for genetic testing. Of
these 77.03% of the claims were paid. Myriad Genetic Laboratories was the
provider for the majority of claims (87.23%) with other claims being filed by
hospitals and other independent labs.
The average age at the time of claim of individuals who were appropriate for
genetic testing is 48.46 years (sd=13.31). Individuals who had a claim for
genetic testing were statistically significantly younger than individuals who were
appropriate for genetic testing but did not have a claim between 2009 and 2012
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for this testing (t=13.63, p<0.0001). When looking specifically at average age by
cancer type, women diagnosed with breast cancer who had testing were
statistically significantly younger than women who did not have testing (t=4.6,
p<0.0001). A significant difference in mean age was not found for women
diagnosed with ovarian or fallopian tube cancer (t=1.61, p=0.1087). These
results are summarized in Table 2.
Table 2: Mean Age of Patient by Cancer Type and Genetic Testing

All Cancer Types
Breast (Female)
Ovarian/FT

Mean Age (SD)
No Genetic Testing Genetic Testing
49.05(13.50)
41.37 (7.83)
43.01 (6.80)
40.79 (6.60)
56.72 (15.95)
50.07 (16.28)

t-value p-value
13.63 <0.0001
4.6
<0.0001
1.61
0.1087

Study demographics show that 83.11% of individuals in this data set who
were identified as appropriate for referral for genetic testing are white, 9.73% are
black and 0.97% are of other race. Of the individuals appropriate for referral to
genetic services who identified as white, 7.85% had a claim for genetic testing,
and 10.13% of individuals who were appropriate for referral and identified as
black had a claim for genetic testing. Of individuals found to be appropriate for
referral to genetic testing, 26.40% received the majority of their services between
2009 and 2012 in Appalachian counties, 71.02% received the majority of their
services in Non-Appalachian counties, and 2.54% only had claims from out of
state. Chi-square testing indicated a statistically significant difference between
Appalachian county designation and genetic testing (ᵡ2=86.66, p<0.0001).Of the
830 individuals in this data set who received the majority of services in
Appalachian counties, 59 (7.10%) had a claim for genetic testing compared to
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6.90% (154 of 2233) of individuals who received the majority of services in nonAppalachian counties. Individuals who had a claim from a gynecologist were
more than twice as likely to receive genetic testing (15.2%) as those who did not
see a gynecologist (7.4%). Individuals who saw an oncologist during the study
period were nearly 3 times more likely to receive genetic testing (16.4%) as those
who did not see an oncologist (5.7%). Distance from a genetic counseling clinic
was calculated using longitude and latitude data of the patients and the cancer
genetic counseling clinics in Kentucky. Distance to the closest clinic was then
categorized and reported for just the full-time cancer genetic counseling clinics
(Main) and for all cancer genetic counseling clinics (including outreach and
telemedicine clinics). These data show that the majority of individuals who had
genetic testing lived within 50 miles of a main cancer genetic counseling clinic
(41.91%). However, chi-square analysis did not show a statistically significant
difference between distance from genetic counseling clinics and genetic testing.
All study demographics and descriptive statistics are summarized in Table 3.
Table 3: Patients for Genetic Services Referral Demographics
Genetic Testing
Total

No

Yes

(n=3144)

(n=2903)

(n=241)

48.46 (13.31)

49.05(13.50)

41.37 (7.83)

106 (3.37%)

106 (3.65%)

0 (0%)

3038 (96.63%)

2797 (96.35%)

241 (100%)

White

2613 (83.11%)

2408 (82.95%)

205 (85.06%)

Black

306 (9.73%)

275 (9.47%)

31 (12.86%)

Other

31 (0.97%)

30 (1.03%)

1 (0.41%)

Not Reported

194 (6.17%)

190 (6.54%)

4 (1.66%)

Ageⱡ
Mean (sd)
Sex*
Male
Female
Race*
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Ethnicity*
Non-Hispanic

2933 (93.29%)

2697 (92.90%)

236 (97.93%)

Hispanic

17 (0.54%)

16 (0.55%)

1 (0.41%)

Not Reported

194 (6.17%)

190 (6.55%)

4 (1.66%)

Yes

830 (26.40%)

771 (26.56%)

59 (24.48%)

No

2233 (71.02%)

2079 (71.62%)

154 (63.90%)

80 (2.54%)

52 (1.79%)

28 (11.62%)

Appalachian County*

Out of state

Distance from Genetic Counseling Clinic (Main)
≤ 50 miles

1371 (43.61%)

1270 (43.75%)

101 (41.91%)

51-100 miles

1042 (33.14%)

962 (33.14%)

80 (33.20%)

101-150 miles

561 (17.84%)

517 (17.81%)

44 (18.26%)

>150 miles

170 (5.41%)

154 (5.30%)

16 (6.64%)

Distance from Genetic Counseling Clinic (Any)
≤ 50 miles

2806 (89.25%)

2588 (89.15%)

218 (90.46%)

51-100 miles

331 (10.53%)

309 (10.64%)

22 (9.13%)

101-150 miles

3 (0.10%)

2 (0.07%)

1 (0.41%)

>150 miles

4 (0.13%)

4 (0.14%)

0 (0%)

Alive

2244 (71.37%)

2037 (70.17%)

207 (85.89%)

Deceased

900 (28.63%)

866 (29.83%)

34 (14.11%)

Yes

105 (3.34%)

89 (3.07%)

16 (6.64%)

No

3039 (96.66%)

2814 (96.93%)

225 (93.36%)

Yes

579 (18.42%)

484 (16.67%)

95 (39.42%)

No

2565 (81.58%)

2419 (83.33%)

146 (60.58%)

2009

1322 (42.05%)

1277 (43.99%)

45 (18.67%)

2010

646 (20.55%)

598 (20.60%)

48 (19.92%)

2011

607 (19.31%)

528 (18.19%)

79 (32.78%)

2012

569 (18.10%)

500 (17.22%)

69 (28.63%)

Vital Status*

Claim from Gynecologist*

Claim from Oncologist*

Year First in Database*

ⱡ t-test shows statistically significant difference in means between genetic testing groups (p
<0.05)
* Chi-square analysis shows statistically significant association between variable and Genetic
Testing (p < 0.05)

Logistic regression was performed to assess which independent variables of
interest contributed to whether recipients of Kentucky Medicaid received genetic
testing. The results of this analysis showed that a number of variables were
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associated with the outcome variable of whether individuals had received genetic
testing. Of note, increasing age was associated with a decrease in the odds of
an individual having genetic testing with a 13.2% decrease in the odds of having
genetic testing for every 5 year increase in age (p<0.0001). Individuals
diagnosed with female breast cancer had 9.137 times the odds of having genetic
testing when compared to those diagnosed with ovarian or fallopian tube cancers
(p<0.0001). Patients who saw a gynecologist during the time span of the study
had 1.81 times the odds of having genetic testing than patients who did not see a
gynecologist (p=0.0083) after controlling for other variables in the model.
Patients who saw an oncologist during the time span of the study had 3.599
times the odds of having genetic testing than those who did not see this type of
specialist (p<0.0001). In this sample, we did not find a statistically significant
difference in genetic testing by race.
Several potential interaction variables were identified utilizing Breslow-Day
tests, and included Appalachian*gynecology, Appalachian*oncology, and vital
status*cancer type. When included in the model, these interaction variables
caused a quasi-separation of data points, and as a result were ultimately
excluded from the final regression model. The odds ratios and confidence
intervals for variables included in the final regression model are summarized in
Table 4.
Diagnostic tests for the logistic regression were used to determine the fit of
the model. The measure of deviance indicated that the model was a good fit
(p=1.0) but the Pearson Goodness of Fit indicated that the model may not be a
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good fit (p=0.0114). The R-squared value indicates that the model explains
22.06% of the variance in the outcome variable, genetic testing. Convergence
criterion were satisfied.
Table 4: Logistic Regression Results for Genetic Testing Outcome
Odds
Parameter
Ratio
Age
0.972
Cancer Type
Ovarian/FT
ref
Female Breast
9.137
Male Breast
<0.001
Race
White
ref
Black
0.873
Other
0.276
Not Reported
0.309
Year First in Database
2009
ref
2010
2.611
2011
5.075
2012
5.212
Claim from a Gynecologist
No
ref
Yes
1.816
Claim from an Oncologist
No
ref
Yes
3.599
Appalachian County
No
ref
Yes
1.24
Out of State
9.355

95% Confidence
Limits
0.960-0.985

p-value
<0.0001

6.155-13.562
<0.001 to >999.999

<0.0001
0.9765

0.633-1.206
0.065-1.170
0.148-0.646

0.4102
0.0807
0.0018

1.931-3.564
3.811-6.759
5.212-3.871

<0.0001
<0.0001
<0.0001

1.166-2.828

0.0083

2.886-4.488

<0.0001

0.973-1.580
6.137-14.260

0.082
<0.0001

D. DISCUSSION
This study was the first to use Medicaid Claims data to determine the use
of genetic testing among individuals who have been diagnosed with breast,
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ovarian, and fallopian tube cancers in Kentucky. This data set was chosen
because there is currently no data set at the state level that includes information
on whether individuals who are appropriate for referral to genetic services are
actually referred and receive those services. While this data set does not provide
complete information on individuals receiving genetic testing, it does provide a
limited view into the use of genetic testing in Kentucky. Furthermore, this data
represents a sample of individuals in the Commonwealth of Kentucky who would
have had full coverage for genetic testing because Kentucky Medicaid provides
full coverage for genetic testing given that a patient meets nationally established
clinical criteria for testing. This was the case during the entire study period, thus
eliminating insurance coverage as a confounding factor that may be important to
consider in other data sets.
The study shows that between 2009 and 2012, 3144 Medicaid recipients
who had been diagnosed with breast, ovarian or fallopian tube cancer met
clinical criteria for referral for genetic counseling and testing. Of these, 214
(7.7%) actually had a claim for genetic testing over the same time period. This
study certainly shows room for improvement in patient referral to and uptake of
genetic testing services in the state of Kentucky among Medicaid recipients.
However, this number is likely an underestimate of the individuals who received
genetic testing. Because cross-sectional data was used, it is likely that some
individuals included in this data set underwent genetic testing either prior to or
after the study period. In addition, a number of individuals may have been
referred for genetic services by their healthcare provider, but decided not to
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proceed with genetic counseling and/or genetic testing after the referral.
Furthermore, individuals utilizing Medicaid are often not continuously enrolled,
and a proportion of those identified in this data set as being appropriate for
referral for genetic testing may have had genetic testing while uninsured or on a
health insurance plan other than Medicaid.
Despite the likelihood that the number of individuals appropriate for
genetic services who received genetic testing shown by the results of this study
is an underestimate, the data does show that a significant number of individuals
are not undergoing the appropriate genetic testing. Genetic testing for HBOC
and other hereditary cancer syndromes not assessed in this study is important
for creating a future cancer screening and prevention plan for individuals who
have already been diagnosed with cancer. Individuals who are found to have
HBOC have a significantly increased risk of developing a second cancer in the
future. However, there are surgical, screening, and medication options available
for those who are found to have HBOC that can either prevent a second cancer
from forming or increase the chances that cancer is found at an early stage if it
were to develop. More recently, genetic test results have also become important
to treatment planning of individuals with a new diagnosis of cancer, specifically
related to surgical interventions for women with breast cancer and treatment with
PARP (poly ADP ribose polymerase) inhibitors in women diagnosed with ovarian
cancer. In addition, genetic testing is important in cancer prevention in the family
members of an index case, and it represents an important method of primary
cancer prevention among those most at risk.
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The logistic regression analysis completed in this study found that a
number of variables were associated with the genetic testing outcome. These
variables included patient age (earliest age of patient recorded in the data set)
cancer type, year the patient first appears in the database, and having a claim
from a gynecologist and/or oncologist. For every 5 years of increased in patient
age, there was a 13.2% decrease in the odds that that person had had genetic
testing (p<0.0001). One explanation for this may be that providers are more
likely to think of genetic counseling services for women who are very young at
the time of diagnosis, but may be less likely to refer patients who are diagnosed
closer to age 50 even though they still meet criteria and should be referred.
Furthermore, women with breast cancer had greater than 9 times the odds of
having had genetic testing than women diagnosed with ovarian or fallopian tube
cancer (p<0.0001). This could be due to a number of factors including
physicians being more knowledgeable about the benefit of genetic testing for
women with breast cancer. Furthermore, women with ovarian cancer are
typically diagnosed at later stages of cancer development, and physicians may
be less likely to refer and/or patients less likely to follow through with the referral
due to other health concerns. Individuals who had seen a gynecologist or
oncologist during the 4 year study period had significantly higher odds of having
genetic testing than those who did not see these physician specialties. However,
only 3.34% (105/3144) of those appropriate for a referral saw a gynecologist, and
only 18.42% (379/3411) saw an oncologist. These logistic regression results
may indicate that Kentucky providers need to be provided with information
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regarding referral to cancer genetic counseling services. Based on the results of
this study, future educational efforts in Kentucky may have more of an impact if
they were focused on primary care and other specialty providers.
Of note, this study did not find a statistically significant association
between patient race and having a claim for genetic testing during the study
period. Although a number of studies have found racial disparities in genetic
counseling and testing16,17, at least one other more recent study did not find this
association18. The current study provides further information regarding race and
genetic testing, and indicates that this disparity, though seen early in the
availability of genetic testing for hereditary cancer syndromes, may be
decreasing over time. However, this finding may also be due in part to race not
being reported for 6.17% of individuals included in this sample and/or that the
population of Kentucky is predominantly composed of individuals who identify as
white. Additional studies will need to be completed in order to determine if
disparities in genetic testing due to race are decreasing.
This study does show that an individual’s odds of having genetic testing
improve in the later years included in the data set. While this shows that
appropriate patients are likely currently being referred more often to genetic
services, the percent of individuals receiving genetic testing remains concerning.
There are a number of reasons why such a small percentage of appropriate
patients for referral to genetic services are actually undergoing genetic testing.
For example, patients may not be referred because providers are unaware of
availability of cancer genetic counseling services. Previous studies have shown
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that lack of provider knowledge about the availability of cancer genetic
counseling services is a barrier to care, even when the genetic counseling
service is located within a provider’s organization22–24.
Correspondence with cancer genetic counseling clinics in Kentucky
indicate that only 12/120 (10%) counties in Kentucky have cancer genetic
counseling services being offered in the county either directly or through
outreach and/or telemedicine. Currently, Kentucky does not maintain an active
list of cancer genetic counseling services in the state, which means that
providers must take extra steps to determine where to refer appropriate patients.
As information on cancer genetic counseling clinics was collected as part of this
study, a list will be submitted to the Kentucky public health genetics coordinator.
Additional studies will be needed in order to determine if lack of knowledge about
genetic counseling services is a barrier to Medicaid providers in the state. If this
is the case, then state-level educational programs for Medicaid providers and
development of resources to aid in education and physician referral need to be
considered by the Kentucky Department for Public Health and state genetics
providers.
Another potential barrier to referral may be lack of knowledge about
insurance coverage of testing. Even though Medicaid has covered genetic
testing of the BRCA1 and BRCA2 genes for a number of years, this fact may not
be widely known outside of providers who regularly provide genetic services or
refer to genetic services. Given that this dataset is looking at an underserved
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population, cost of genetic testing would likely be a concern of both providers and
patients when considering referral or following through on a referral.
Focusing on increasing referrals among the Kentucky population receiving
Medicaid will only grow in importance in the future given the 2014 Medicaid
expansion in Kentucky. As stated previously, additional educational programs
should be considered for providers in the state to increase the awareness of
genetic counseling services and clinical guidelines for referral. This study also
provides evidence to support the implementation of strategies outlined in the
CDC’s Tier 1 Genomic Applications Toolkit for increasing the number of patients
who are identified as appropriate for genetic counseling. Strategies suggested in
the toolkit that could be considered by Kentucky include bidirectional cancer
registry reporting, which is a process where the cancer registry uses national
guidelines for referral of individuals diagnosed with cancer to genetic counseling
services to identify cases that should be referred and then sending this
information as well as educational materials on hereditary cancer syndromes
back to reporting institutions to help in patient identification. Other strategies
could include evaluating the policies of Medicaid insurance providers to
determine if clear guidelines for coverage of genetic testing are in place and
readily available to healthcare providers and developing methods to assess the
awareness and use of genetic testing among the general population in Kentucky,
such as developing new questions for the state Behavioral Risk Factor
Surveillance System (BRFSS) about genetic testing.
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The limitations of this study are due mainly to the data set used for this
secondary data analysis. First, the Kentucky Medicaid Claims database is only
as complete and as accurate as the information being submitted by providers. It
is possible that there are claims for genetic testing for Medicaid members that
are not included in the data set requested. During the data cleaning process, a
number of entries were found with misinformation (for example, a patient is
coded as being female when all other claims for the same individual indicate that
the person is a male). Considerable effort to correct these type of entries was
made, but misinformation may still exist in the data set. As stated previously,
there are a number of factors that make it likely that the estimate of the number
of appropriate individuals for genetic referral who received genetic testing (7.7%)
is an underestimate. However, the number of individuals appropriate for referral
to genetic services for HBOC is also likely an underestimate. The three clinical
criteria used in this study to identify appropriate patients (individuals diagnosed
with breast cancer under age 50, all individuals diagnosed with male breast
cancer, and all individuals diagnosed with ovarian or fallopian tube cancer) will
miss a number of members who are appropriate for genetic services including
those with a family history of breast, ovarian, or other cancers, those with a
known BRCA1 and BRCA2 mutation in the family, those with triple negative
breast cancer diagnoses and those diagnosed with multiple cancers. However,
there is currently no state-level data that contains the type of information needed
to identify some of these individuals who are appropriate for referral, and utilizing
this Medicaid data provides a useful first step to assessing the need for
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increased education, programs, and genetic services to ensure that at-risk
individuals are being referred to cancer genetic services.
While this study provides useful information for a Kentucky state-wide
needs assessment regarding cancer genetic counseling and testing, it only
addresses the issue in one set of individuals. Additional research will need to be
done to ascertain the use of genetic testing by individuals with insurance
coverage from other companies. This will provide a more comprehensive picture
of genetic testing in Kentucky and would be useful for future program
development by the Kentucky Department of Public Health and genetics
providers. The results of this study will not be generalizable to all other states
given the specific and limited nature of the data used for this secondary data
analysis, but may be generalizable to states with similar population
demographics and availability of genetic counseling services. Other researchers
can use this study as an example to begin examining the use of cancer genetic
counseling services in their own states. It is only through the generation of
evidence that the need for increased education and programming for public
health genetic issues will make its way to the agenda of healthcare facilities,
policy makers, and public health departments.
In conclusion, this study shows that there is a significant difference
between the number of individuals who are appropriate for referral to cancer
genetic services and those who actually receive services. This study has
identified potential variables that are associated with increased odds of a patient
receiving genetic testing. This information can be used to begin developing a
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plan for programming addressing public health genetics issues in the state of
Kentucky in the future. The CDC has released information and resources for
states on program implementation that can help improve the health of state
citizens by disease prevention and early detection. This study demonstrates the
impact that implementing programs to increase referrals of appropriate
individuals for cancer genetic services can have on cancer prevention and early
detection in Kentucky.
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CHAPTER 4
IMPLICATIONS FOR PUBLIC HEALTH
A. INTRODUCTION
B. SUMMARY OF RESULTS
C. CONCLUSIONS
D. IMPLICATIONS
E. RECOMMENDATIONS

A. INTRODUCTION
The need for state policies and programs in public health genetics
and genomics is expanding beyond the traditional role of providing
newborn screening and the associated follow-up of abnormal screen
results. There is significant evidence that genetic testing for predisposition
diseases across the lifespan can prevent serious illness and even
premature death in individuals who are found to have a genetic mutation
that puts them at high risk for disease. In the field of cancer genetics,
genetic testing for Hereditary Breast and Ovarian Cancer syndrome
(HBOC) and Lynch syndrome (LS) has been shown to provide beneficial
information for affected individuals who can then take steps to reduce the
risk for cancer associated with one of these syndromes. Despite this
evidence, the majority of individuals with these two conditions remain
unaware of their risk because they have not been referred for genetic
counseling and/or testing.
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In order to bring attention to the importance of utilizing evidencebased testing for hereditary cancer syndromes and other inherited
conditions, the CDC has released information ranking genetic tests and
family history applications for genetic diseases based on the level of
available evidence. The CDC has also developed resources to help state
and local health departments implement policy and programs for
addressing those diseases with the highest ranking, or Tier 1 Genomic
Applications. Several pioneer states have been working for over a decade
to improve awareness of and access to services for inherited cancer,
cardiac, and other syndromes. These states, however, have been the
exception, and the majority of states have not taken steps to address this
expanded focus of public health genetics.
The aim of this dissertation was to conduct the first studies in
Kentucky to determine the need for public health genetics programs for
hereditary cancer syndromes. In order to conduct these assessments,
data sources first needed to be identified. At this time, there is no state or
national database that provides the information needed to identify all
individuals who might be appropriate for referral for cancer genetic
services or to determine who has received genetic testing and what the
outcome of that testing was. It is also likely that few data sources exist in
local environments, but these may be increasing due to the use of
electronic medical records. As a result, this needs assessment was
conducted using two pre-existing data sources: Kentucky Cancer Registry
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data and Kentucky Medicaid Claims data. The studies in this dissertation
were planned and completed in a manner that the data could be readily
used to show the need for public health genomics programs and could be
easily reproduced in other states that are also embarking on a needs
assessment in this emerging specialty area of public health. The
concluding chapter of this dissertation will briefly summarize the results of
the two studies presented in Chapters 2 and 3. Based on those results,
conclusions are drawn, and the implications of these studies both in
Kentucky and in other states are discussed. Finally, recommendations for
future action and research are outlined. The two studies contained in this
dissertation represent the first effort to assess the need for public health
action in Kentucky to address HBOC and LS.
B. SUMMARY OF RESULTS
Paper 1, “An Assessment of Kentucky Cancer Registry Data for
Appropriate Referral to Genetic Services for Hereditary Breast and
Ovarian Cancer syndrome and Lynch syndrome, 2009-2012,” utilized
Kentucky Cancer Registry data to determine the number of individuals
diagnosed with cancer between 2009 and 2012 who would meet select
nationally established clinical criteria for referral to genetic counseling
services. The study also assessed whether the current genetic
counselors employed in Kentucky would be able to manage the increase
in referrals that would likely result from the implementation of programs to
increase patient identification. The results of Paper 1 show that there are
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a significant number of individuals diagnosed with breast, ovarian,
fallopian tube, endometrial and colorectal cancers each year in Kentucky
who are appropriate for referral for genetic services for HBOC or LS.
Between 2009 and 2012, 15,477 breast, ovarian, fallopian tube,
endometrial and colorectal cancers (55.1% of all diagnosed cases of these
cancers during the same time period) were determined to be appropriate
for referral to genetic services. The cases that were identified as
appropriate for referral had an overrepresentation of diagnoses at more
advanced stages (Stage 3 or 4 33.21%) and of diagnoses under the age
of 50 (31.08%), largely due to young age at diagnosis being an indicator
for referral.
An analysis of appropriate cases for referral by county in 2012
showed that every county had residents who were diagnosed with one of
the cancers included in this study and were appropriate for referral. The
highest number of cases occurred in Jefferson County (n=729, 18.38% of
cases identified in Kentucky), Fayette County (n=255, 6.43% of cases
identified in Kentucky) and Kenton County (n=108, 2.72% of cases
identified in Kentucky). These three counties also house all of the full-time
on-site genetic counseling services in Kentucky. Genetic counselors at
these institutions provide outreach and/or telemedicine services in 9
additional counties; however, 90% of Kentucky counties do not have
genetic counseling services available in the county. Area development
districts (ADDs) were also assessed for appropriate cases and genetic
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counseling services. The study found that 75% of individuals who were
identified as appropriate for referral to genetic services in 2012 would
have been able to access these services in their ADD. Six of the 15 ADDs
lack locally available genetic counseling services. This data was
presented as count data in order to illustrate the need for genetic
counseling services across the state and to provide local leaders with a
tangible number of people who would utilize these services.
An assessment of genetic counselors in Kentucky shows that there
are currently 10.5 genetic counselors providing cancer genetic counseling
services in the state. This study estimates that at minimum 10 genetic
counselors will be needed just to provide services to individuals newly
diagnosed with cancer in Kentucky each year and their relatives.
Additional genetic counselors will be needed to provide services to those
individuals previously diagnosed with cancer who did not receive genetic
counseling, individuals who have not been diagnosed with cancer but are
appropriate for referral, individuals at risk for hereditary cancer syndromes
other than HBOC and LS, and individuals diagnosed with cancer who
have a family history of cancer suggestive of HBOC or LS. Should a
state-wide program be implemented to improve identification of patients
appropriate for referral to genetic services, Kentucky does not have the
genetic professional workforce to manage the increase in referrals.
Paper 2, “Utilizing Medicaid Claims Data to Assess the Use of
Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome in
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Kentucky and Characteristics that Influence Genetic Testing Completion,”
is a secondary data analysis of Kentucky Medicaid Claims data between
2009 and 2012 for individuals who had a claim with an associated
diagnosis code for breast cancer (174.*), male breast cancer (175.*),
ovarian cancer (183.0) or fallopian tube cancer (183.2). This data analysis
determined that during the time span of this study, 3144 individuals had a
claim associated with one of the cancers of interest in this study and met
the outlined criteria for referral to genetic services. This included 1849
women diagnosed with breast cancer under age 50, 74 males diagnosed
with breast cancer, and 1221 women diagnosed with ovarian or fallopian
tube cancer. Of these individuals, 241 (7.7%) had a claim for genetic
testing.
Several variables were found to be associated with the outcome
variable genetic testing (yes/no). Logistic regression showed that for
every 5 year increase in patient age (earliest age at the time of claim
included in the data set), the odds of an individual having genetic testing
decreased by 13.2% (p<0.0001). Cancer type also significantly affected
whether an individual had a claim for genetic testing with women
diagnosed with breast cancer having 9.137 times the odds of having
testing than women diagnosed with ovarian or fallopian tube cancer
(p<0.0001). No males diagnosed with breast cancer identified in this data
set had a claim for genetic testing, despite 25% or more of male breast
cancers being due to HBOC. Having one or more claims from a
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gynecologist (p=0.0083) or oncologist (p<0.0001) during the study period
also increased a person’s odds of having a genetic testing claim.
This study found that several variables previously discussed in the
literature as having an effect on referral to and/or uptake of genetic testing
were not statistically significantly associated with having a genetic testing
claim. These included race, distance from a genetic counseling clinic, and
living in an Appalachian designated county.
C. CONCLUSIONS
When considered together, the two studies included in this
dissertation provide preliminary information regarding the need for and
use of genetic testing for hereditary cancer syndromes in Kentucky.
Paper 1 shows that there are a significant number of individuals
diagnosed with cancer each year who should be referred for genetic
counseling and testing services in Kentucky, and Paper 2 provides
evidence that the utilization of genetic testing services is low. This
information should be used to begin discussions with state and local public
health leaders about the importance of further investigating the role of
public health genetics in Kentucky. Genetics providers should also be
engaged and encouraged to share best practices among clinics and with
public health leaders. Genetic providers can also likely provide valuable
information about the barriers in Kentucky to obtaining patient referrals
and providing services that can then be taken into account during future
public health genetics program development. Given the results of this
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dissertation, developing policies and programs to increase awareness and
knowledge of genetic counseling for hereditary cancer syndromes should
also be strongly considered. Programs designed to more uniformly
provide referrals to at-risk individuals should also be considered. It would
also be important to involve the genetic counseling community in helping
to develop strategies for expanding the genetic counseling workforce, as
these studies suggest that if programs were implemented to increase
referral to and use of genetic counseling services, it is likely that the
genetic counseling workforce in Kentucky would need to increase.
The results of these studies also begin to show the type of impact
that an increase in referral to genetic counseling services can have on
cancer prevention in Kentucky. Two of the cancers for which individuals
with HBOC are at increased risk, breast and ovarian cancers, are the
second and fifth causes of cancer deaths in women. It is estimated that
HBOC is responsible for approximately 5% of female breast cancer (9.5%
of breast cancers diagnosed under age 50) and up to 18% of ovarian
cancers5,6,8. It is estimated that LS causes 2-4% of colon cancers12. If
individuals with these hereditary cancer syndromes were routinely
identified before cancer developed, there are screening and prevention
methods that can significantly reduce the risks for these cancers. Based
on the data obtained from the Kentucky Cancer Registry, 192 cases of
breast cancer (5% of 3846 diagnoses), 54 ovarian and fallopian tube
cancers (18% of 303) and 50 colon cancers (2% of 2470) could have been
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prevented in 2012 alone had individuals with HBOC and LS been
uniformly identified on a consistent basis prior to cancer development or
diagnosed at earlier stages through increased screening. Of course, not
all patients identified through these programs would choose to pursue
genetic testing, but all individuals should be informed about the availability
of testing.
D. IMPLICATIONS
The results of this dissertation have implications for public health
practice in Kentucky and other states. Although the information contained
in this dissertation is specific to Kentucky, it is likely that similar situations
exist in other states that have not previously done significant work with
genetic conditions that have tier 1 genomic applications. Each state will
have unique circumstances and will need to conduct an independent
needs assessment, but it is likely that the methods used in this
dissertation can be replicated in other states with similar sources of data.
In Kentucky, these results have a number of implications for the
public health, healthcare, and genetic services workforces. Currently,
public health genetics in Kentucky focuses solely on newborn screening
and short term follow-up of infants with positive screening results. The
results of this dissertation have revealed a significant gap in public health
services in Kentucky that would have a significant impact on cancer
prevention efforts. When considering public health genetics and cancer,
the state of Kentucky currently fulfills none of the 10 Essential Public
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Health Services, but this research provides preliminary information to
monitor health status, investigate health problems, and inform, educate
and empower people about the health issue of hereditary cancer. Unlike
other screening and prevention programs for cancer, identifying
individuals at risk for hereditary cancer syndromes allows for targeted
interventions in individuals with the highest risks of developing cancers.
While traditional cancer prevention programs remain important, we cannot
continue to ignore the unique needs of individuals with hereditary cancer.
While resources would certainly need to be allocated to growing public
health genetics in Kentucky and educating the existing public health
workforce about the importance of genetics in the care of patients with
common disease such as cancer, these efforts have the potential for
significant benefits.
Although cancer genetic services have been offered in Kentucky
since the introduction of BRCA1 and BRCA2 testing, these services have
often been fragmented. Kentucky currently does not have a state genetics
professional organization, regular meetings for genetics professionals, or
a consistent method for genetic professionals to share ideas and best
practices. If we are to move genetic counseling for hereditary cancer
syndromes from a one provider, one patient model to a public health
based model, the genetic counseling community in Kentucky will need to
address these issues. An expansion of public health genetics in Kentucky
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will be most successful if a unified effort is made by the genetic counseling
community to promote the importance of such programs.
E. RECOMMENDATIONS
The results from this dissertation provide a significant contribution
to the literature regarding genetic counseling and testing in Kentucky,
specifically for the Tier 1 Genomic Applications for HBOC and LS. Based
on these results, it is recommended that the state health departments,
local health departments, genetic providers and healthcare institutions in
Kentucky begin to consider the growing impact of genetics on cancer
screening, prevention and treatment. The first step in this process is
education. Public health workers, healthcare providers and the public
need to be educated about genetics and the importance of genetic risk
assessment and testing in cancer prevention. Furthermore, a focus on
increasing awareness of genetic services in Kentucky is imperative.
Although genetic counseling services are only provided full-time on site in
three cities (Louisville, Lexington, and Covington) there are a number of
outreach clinics and telemedicine clinics available to residents who live
outside these cities. However, it would be difficult for providers to refer to
these services if they are unaware of their availability. Currently, Kentucky
does not have a listing of genetic counselors providing services in the
state or any other state-wide resources regarding genetic testing and
hereditary cancer syndromes.
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In order to assure services to those who are at risk for hereditary
cancer syndromes, new and innovative programs will need to be
considered as the model for genetic services transitions from a one
provider, one patient model to population based methods. One type of
program that has been implemented in other states and is included in the
CDC’s Tier 1 Genomic Applications Toolkit is bidirectional cancer registry
reporting. Bidirectional cancer registry reporting involves applying
evidence-based guidelines for the identification of individuals at-risk for
hereditary cancer syndromes to the submitted case data to identify those
individuals diagnosed with cancer in the state who should have a referral
to genetic counseling services. This information is then reported back to
the healthcare institutions, physicians, and/or patients directly along with
information about hereditary cancer and accessing genetic counseling
services. Given that state cancer registries receive information on all
cases of cancer diagnosed in a state, this type of program helps to
promote uniform referral of appropriate patients. This would help to
overcome some of the disparities associated with genetic counseling
identified in this dissertation. Specifically, this type of program would help
to reach individuals who live in Appalachian counties, see physicians who
are not aware of genetic counseling services or referral criteria, or are not
diagnosed at a very young age with cancer. Recently, the CDC and the
Genetic Alliance have worked to create additional resources for states
interested in implementing bidirectional cancer registry reporting
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programs, including an educational video about bidirectional cancer
registry reporting for providers, written materials that can be used to report
back cancer registry data to institutions, and educational information for
providers and patients including a full length slide set on HBOC and LS 34.
Although this dissertation is the first to assess the need in Kentucky
for cancer genetic counseling services, additional research needs to be
done in order to further determine the specific needs of Kentucky
residents that should be considered as public health genetics and
genomics programs are planned and implemented. Additional studies
should focus on:
1. Determining provider identified barriers to referring patients for
genetic counseling for hereditary cancer syndromes.
2. Exploring methods to document cancer family history and barriers
to the accurate documentation of this information. A future study
on this topic could look at the family history question currently
included in data reported to the Kentucky Cancer Registry. Key
informant interviews could then be carried out with cancer registrars
and/or providers at healthcare organizations to determine barriers
to accurately documenting this information. The development and
inclusion of additional family history questions on the Kentucky
Cancer Registry abstracting forms to more accurately document
family history for identification of appropriate patients for genetic
services should also be explored.
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3. Assessment of current programs in Kentucky being conducted by
genetics professionals, healthcare systems, state public health
departments, and local public health departments that include
information on genetics and genomics related to Tier 1 Genomic
Applications or could have this information easily assimilated into
the existing program. By understanding what is currently being
done in Kentucky, gaps can be identified and addressed in the
development and implementation of future programs. Having
documentation of current efforts in public health genomics will also
help to prevent duplication of efforts and resources.
4. Review health insurance plans in Kentucky to determine whether
these plans have guidelines that follow the national, evidencebased guidelines for referral to cancer genetic services.
5. Implementation of a pilot project of bidirectional cancer registry
reporting. The Kentucky Cancer Registry is a valuable resource to
the state of Kentucky and has the potential to play an important role
in the advancement of public health genetics and genomics in the
state.
These studies and others will be needed in order to more fully
understand how to implement programs that will best address the needs
of Kentucky residents. However, conducting these studies and pilot
projects will require funding and time, both of which are in short supply.
Currently, there is sparse funding for public health genetics and genomics
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outside of newborn screening, although some resources do exist.
Funding sources include the CDC Office of Public Health Genomics,
Healthy People 2020 grants, and other grant resources. The preliminary
information contributed by this dissertation combined with the results of
future studies could be utilized to help secure grant funding for Kentucky
in the future.
A second barrier to implementing programs in public health genetics in
the state of Kentucky is the sparse genetic counseling workforce. Just as
there is little funding available for public health genetics and genomics, it
can be difficult to justify the addition of genetic counselors in a healthcare
system because these departments often do not produce significant
revenue. This is partially due to the way that genetic counseling services
can be billed, which can be especially difficult if the state does not license
genetic counselors, as is the case in Kentucky. Recently, there has been
an effort to pass a licensure bill at the state level to establish licensure for
genetic counselors, and these efforts are ongoing. Public health
practitioners and healthcare systems should support these efforts moving
forward as this is an important step in expanding the genetic counseling
workforce and preparing Kentucky for the increasing need for genetic
services.
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APPENDIX 1
Cancer Genetic Counseling Clinics in Kentucky April 2015
Genetic
Counseling
Clinic Main
Site

University of
Louisville

Kentucky One
Norton
Healthcare

Baptist Health
Lexington

University of
Kentucky
St. Elizabeth
Healthcare

County

Jefferson

ADD

KIPDA

Cancer Outreach
Clinics

County

ADD

Brown Cancer Center
Baptist Hospital East
St. Mary's Hospital (IN)

Jefferson
Jefferson
n/a

KIPDA
KIPDA
n/a

St. Joseph Hospital
St. Joseph Hospital
East

Fayette

Bluegrass

Fayette

Bluegrass

Daviess

Green River

Nelson

Lincoln Trail

Baptist Health Madison

Madison

Bluegrass

Baptist Health Cordin
Hardin Memorial Health
Baptist Health
Madisonville

Whitley
Hardin

Cumberland
Valley
Lincoln Trail

Hopkins

Pennyrile

Rowan
Perry

Gateway
Kentucky
River

Campbell

Northern
Kentucky

Jefferson

KIPDA

Mitchell Memorial
Cancer Center
Flaget Memorial
Hospital
None

Jefferson

KIPDA

None

Fayette

Fayette

Kenton

Bluegrass

Bluegrass

Northern
Kentucky

St. Claire Regional
Medical Center*
Hazard ARH Medical
Mall
St. Elizabeth Ft.
Thomas
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